<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Bisphosphonate therapy for osteogenesis imperfecta - Dwan, K - 2016 | Cochrane Library</title> <meta content="Bisphosphonate therapy for osteogenesis imperfecta - Dwan, K - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005088.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Bisphosphonate therapy for osteogenesis imperfecta - Dwan, K - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005088.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005088.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Bisphosphonate therapy for osteogenesis imperfecta" name="citation_title"/> <meta content="Kerry Dwan" name="citation_author"/> <meta content="Cochrane Central Executive" name="citation_author_institution"/> <meta content="Carrie A Phillipi" name="citation_author"/> <meta content="Oregon Health &amp; Science University" name="citation_author_institution"/> <meta content="Robert D Steiner" name="citation_author"/> <meta content="Donald Basel" name="citation_author"/> <meta content="Division of Genetics. MC#716" name="citation_author_institution"/> <meta content="dbasel@mcw.edu" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD005088.pub4" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/10/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005088.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005088.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005088.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Bone Density [drug effects]; Bone Density Conservation Agents [administration &amp; dosage, *therapeutic use]; Diphosphonates [administration &amp; dosage, *therapeutic use]; Fractures, Bone [*prevention &amp; control]; Injections, Intravenous; Osteogenesis Imperfecta [*drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005088.pub4&amp;doi=10.1002/14651858.CD005088.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="tIsQXAzh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005088\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005088\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005088\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005088\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005088.pub4",title:"Bisphosphonate therapy for osteogenesis imperfecta",firstPublishedDate:"Oct 19, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005088.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005088.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005088.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005088.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005088.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005088.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005088.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005088.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005088.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005088.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8681 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005088.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/full#CD005088-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/full#CD005088-sec-0125"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/full#CD005088-sec-0022"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/full#CD005088-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/full#CD005088-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/full#CD005088-sec-0051"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/full#CD005088-sec-0119"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/table_n/CD005088StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/table_n/CD005088StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Bisphosphonate therapy for osteogenesis imperfecta</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/information#CD005088-cr-0002">Kerry Dwan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/information#CD005088-cr-0003">Carrie A Phillipi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/information#CD005088-cr-0004">Robert D Steiner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005088.pub4/information#CD005088-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Donald Basel</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/information/en#CD005088-sec-0136">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 October 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005088.pub4">https://doi.org/10.1002/14651858.CD005088.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005088-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005088-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005088-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005088-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005088-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005088-abs-0001" lang="en"> <section id="CD005088-sec-0001"> <h3 class="title" id="CD005088-sec-0001">Background</h3> <p>Osteogenesis imperfecta is caused by a genetic defect resulting in an abnormal type I collagen bone matrix which typically results in multiple fractures with little or no trauma. Bisphosphonates are used in an attempt to increase bone mineral density and reduce these fractures in people with osteogenesis imperfecta. This is an update of a previously published Cochrane Review. </p> </section> <section id="CD005088-sec-0002"> <h3 class="title" id="CD005088-sec-0002">Objectives</h3> <p>To assess the effectiveness and safety of bisphosphonates in increasing bone mineral density, reducing fractures and improving clinical function in people with osteogenesis imperfecta. </p> </section> <section id="CD005088-sec-0003"> <h3 class="title" id="CD005088-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Inborn Errors of Metabolism Trials Register which comprises references identified from comprehensive electronic database searches, handsearches of journals and conference proceedings. We additionally searched PubMed and major conference proceedings. </p> <p>Date of the most recent search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Inborn Errors of Metabolism Register: 28 April 2016. </p> </section> <section id="CD005088-sec-0004"> <h3 class="title" id="CD005088-sec-0004">Selection criteria</h3> <p>Randomised and quasi‐randomised controlled trials comparing bisphosphonates to placebo, no treatment, or comparator interventions in all types of osteogenesis imperfecta. </p> </section> <section id="CD005088-sec-0005"> <h3 class="title" id="CD005088-sec-0005">Data collection and analysis</h3> <p>Two authors independently extracted data and assessed the risk of bias of the included trials. </p> </section> <section id="CD005088-sec-0006"> <h3 class="title" id="CD005088-sec-0006">Main results</h3> <p>Fourteen trials (819 participants) were included. Overall, the trials were mainly at a low risk of bias, although selective reporting was an issue in several of the trials. Data for oral bisphosphonates versus placebo could not be aggregated; a statistically significant difference favouring oral bisphosphonates in fracture risk reduction and number of fractures was noted in two trials. No differences were reported in the remaining three trials which commented on fracture incidence. Five trials reported data for spine bone mineral density; all found statistically significant increased lumbar spine density z scores for at least one time point studied. For intravenous bisphosphonates versus placebo, aggregated data from two trials showed no statistically significant difference for the number of participants with at least one fracture, risk ratio 0.56 (95% confidence interval 0.30 to 1.06). In the remaining trial no statistically significant difference was noted in fracture incidence. For spine bone mineral density, no statistically significant difference was noted in the aggregated data from two trials, mean difference 9.96 (95% confidence interval ‐2.51 to 22.43). In the remaining trial a statistically significant difference in mean per cent change in spine bone mineral density z score favoured intravenous bisphosphonates at six and 12 months. Data describing growth, bone pain, and functional outcomes after oral or intravenous bisphosphonate therapy, or both, as compared to placebo were incomplete among all studies, but do not show consistent improvements in these outcomes. Two studies compared different doses of bisphosphonates. No differences were found between doses when bone mineral density, fractures, and height or length z score were assessed. One trial compared oral versus intravenous bisphosphonates and found no differences in primary outcomes. Two studies compared the intravenous bisphosphonates zoledronic acid and pamidronate. There were no significant differences in primary outcome. However, the studies were at odds as to the relative benefit of zoledronic acid over pamidronate for lumbosacral bone mineral density at 12 months. </p> </section> <section id="CD005088-sec-0007"> <h3 class="title" id="CD005088-sec-0007">Authors' conclusions</h3> <p>Bisphophonates are commonly prescribed to individuals with osteogenesis imperfecta. Current evidence, albeit limited, demonstrates oral or intravenous bisphosphonates increase bone mineral density in children and adults with this condition. These were not shown to be different in their ability to increase bone mineral density. It is unclear whether oral or intravenous bisphosphonate treatment consistently decreases fractures, though multiple studies report this independently and no studies report an increased fracture rate with treatment. The studies included here do not show bisphosphonates conclusively improve clinical status (reduce pain; improve growth and functional mobility) in people with osteogenesis imperfecta. Given their current widespread and expected continued use, the optimal method, duration of therapy and long‐term safety of bisphosphonate therapy require further investigation. In addition, attention should be given to long‐term fracture reduction and improvement in quality of life indicators. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005088-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005088-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005088-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005088-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005088-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005088-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD005088-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005088-abs-0003" lang="en"> <h3>Bisphosphonate therapy for osteogenesis imperfecta</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effect and safety of bisphosphonates in increasing bone mineral density, reducing fractures and improving clinical function in people with osteogenesis imperfecta. This is an update of a previously published Cochrane Review. </p> <p><b>Background</b> </p> <p>Osteogenesis imperfecta is also known as brittle bone disease. It is a genetic condition which can be passed on from a parent to child or occur in the child without any other family history. An affected person is at risk for frequent breaks of the long bones or collapse of the bones of the spine. There is no cure for osteogenesis imperfecta and treatment is mostly supportive. </p> <p><b>Search date</b> </p> <p>The evidence is current to: 28 April 2016.</p> <p><b>Study characteristics</b> </p> <p>This review looked at trials studying one of the groups of medications known as bisphosphonates which are more typically used to treat osteoporosis. They are used in osteogenesis imperfecta to try and reduce the number of bone fractures in affected individuals. </p> <p>We included 14 trials, and most of these did not show a major reduction in fractures in affected individuals when treated with bisphosphonates. </p> <p><b>Key results</b> </p> <p>Each trial independently showed significant improvements in bone mineral density after treatment with oral or intravenous bisphosphonates. Bone pain, growth and quality of life indicators were not reported in enough detail and the effects of this treatment need further investigation. The long‐term effectiveness and safety of bisphosphates, as well as dose and duration of therapy, require extended evaluation </p> <p><b>Quality of the evidence</b> </p> <p>The majority of trials analysed were small and not powered to show a statistically significant difference in many outcome measures. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005088-sec-0125" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005088-sec-0125"></div> <h3 class="title" id="CD005088-sec-0126">Implications for practice</h3> <section id="CD005088-sec-0126"> <p>The results from the included trials provide evidence for statistically significant improvement in BMD in individuals affected with OI when treated with either oral or IV bisphosphonates. It remains to be seen whether this increase in BMD is a surrogate marker for fracture reduction and clinical functional improvement. At this time, comparative data remains inconclusive though several trials reported here individually show improvements in fracture incidence. Additionally, the long‐term safety of bisphosphonates in OI, particularly when used in children, and the risk of bisphosphonates to cause atypical femur fractures, impair perioperative or fracture bone healing (or both), as well as increased bone density if unmonitored, have not been sufficiently evaluated. The duration of use once BMD is improved requires thoughtful study. Effects of bisphosphonates on growth, bone deformity, mobility, and pain have been reviewed but absolute benefits remain inconclusive, </p> </section> <h3 class="title" id="CD005088-sec-0127">Implications for research</h3> <section id="CD005088-sec-0127"> <p>Despite widespread use, a number of questions concerning bisphosphonate therapy in children and adults with OI remain unanswered. In particular whether increases in BMD convincingly translate into fracture reduction and functional improvement. </p> <p>Additionally, the following remain unclear.</p> <p> <ul id="CD005088-list-0005"> <li> <p>Are bisphosphonates equally safe and effective in children and adults? What are the long‐term effects of osteoclast inhibitors like bisphosphonates on the immature growing skeleton? Will they be licensed for use in children (<a href="http://www.fda.gov/cder/foi/esum/2003/20560se1-038BPCA.PDF" target="_blank">www.fda.gov/cder/foi/esum/2003/20560se1‐038BPCA.PDF</a>)? </p> </li> <li> <p>Are there differences in the safety or efficacy of IV versus oral bisphosphonates? Are there differences in safety and efficacy of individual bisphosphonates in OI? Does the optimal method, dosage, length of therapy as well as optimal therapeutic window also warrant investigation? </p> </li> <li> <p>Will the efficacy of bisphosphonates in increasing BMD be confirmed in larger studies, and with more heterogeneous participants? Does the efficacy of bisphosphonates differ by OI clinical type or mutation type? Are bisphosphonates useful in OI types which do not increase bone turnover? </p> </li> <li> <p>Do bisphosphonates, when used in people with OI, delay or impair fracture healing, or peri‐operative bone healing? </p> </li> </ul> </p> <p>Well‐designed, adequately‐powered, placebo‐controlled RCTs assessing the longitudinal effects of bisphosphonates on BMD, fracture reduction and healing, and changes in quality of life indicators such as function and pain should be studied in both children and adults with OI. These trials should be prospective, longitudinal, double‐blinded, using comparable assessments of change including z scores for BMD and vertical growth, as well as validated assessments measuring pain and quality of life outcomes. Quality of life outcomes should be broadened to include other factors important to people with OI, such as hearing and dentition and biochemical markers of bone turnover should be carefully assessed to determine if they are an adequate proxy for dose efficacy and subject concordance with therapy. Spontaneous versus non‐spontaneous fractures should be investigated in these trials as well as bone healing after fractures and operative intervention with bisphosphonates. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005088-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005088-sec-0022"></div> <p>A definition of terms is available at: <a href="http://www.cochrane.org/glossary" target="_blank">www.cochrane.org/glossary</a>. </p> <section id="CD005088-sec-0023"> <h3 class="title" id="CD005088-sec-0023">Description of the condition</h3> <p>Osteogenesis imperfecta (OI) is an inherited, and most often autosomal dominant condition, caused by mutations in genes encoding type I collagen (<a href="./references#CD005088-bbs2-0060" title="SteinerRD , AdsitJ , BaselD . Gene Reviews; COL1A1/2‐Related Osteogenesis Imperfecta. http://www.ncbi.nlm.nih.gov/books/NBK1295/ (Initial Posting: January 28, 2005; Last Update: February 14, 2013). ">Steiner 2013</a>). Several recessive genetic defects have been identified as causing OI. This condition (sometimes called brittle bone disease) is characterized by bone fragility, and predisposition to fractures, in many cases with minimal or no trauma. Low bone mass is a common but not universal feature. In addition to multiple fractures, individuals with OI also commonly exhibit joint hypermobility, blue or grey‐blue scleral colour, dentinogenesis imperfecta (a genetic disorder of tooth development), and premature hearing loss (<a href="./references#CD005088-bbs2-0036" title="ColeWG . Advances in Osteogenesis Imperfecta. Clinical Orthopaedics and Related Research2002;401:6‐16. ">Cole 2002</a>). </p> <p>Type I collagen is the most abundant protein of bone and is also present in ligaments, tendons, dentin, sclera, and skin. Normal bone matrix is composed of 90% Type I collagen fibers and 10% non‐collagenous proteins. These collagen fibers are usually oriented in a preferential direction with hydroxyapatite [Ca10(PO4)6(OH)2] crystals located in the ground substance within these fibers. Hydroxyapatite crystals provide mechanical rigidity and strength to bone whereas collagen fibers provide resilience. Individuals with OI have less or poorer quality (or both) type‐I collagen than unaffected people, causing their bones to deform or fracture (or both). In 80% to 90% of people with OI, mutations in one of the two genes encoding type I collagen chains, COL1A1 and COL1A2, are found (<a href="./references#CD005088-bbs2-0027" title="ByersPH , WallisGA , WillingMC . Osteogenesis imperfecta: translation of mutation to phenotype. Journal of Medical Genetics1991;28(7):433‐42. ">Byers 1991</a>). </p> <p>The exact incidence of OI is unknown as milder forms may be unrecognized. Finnish data published in 2002 by Kuurila suggests six per 100,000 individuals are affected with the disorder (<a href="./references#CD005088-bbs2-0049" title="KuurilaK , KaitilaI , JohanssonR , GrenmanR . Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey. The Annals of Otology, Rhinology, and Laryngology2002;111(10):939‐46. ">Kuurila 2002</a>). Other studies suggest the incidence of severe OI may be as high as 1 in 25,000 live births (<a href="./references#CD005088-bbs2-0029" title="ByersPH . Osteogenesis imperfecta: perspectives and opportunities. Current Opinion in Pediatrics2000;12(6):603‐9. ">Byers 2000</a>; <a href="./references#CD005088-bbs2-0037" title="ConnorJM , ConnorRA , SweetEM , GibsonAA , PatrickWJ , McNayMB , et al. Lethal neonatal chondrodysplasias in the West of Scotland 1970‐1983 with a description of a thanatophoric, dysplasialike, autosomal recessive disorder, Glasgow variant. American Journal of Medical Genetics1985;22(2):243‐53. ">Connor 1985</a>; <a href="./references#CD005088-bbs2-0054" title="OrioliIM , CastillaEE , ScaranoG , MastroiacovoP . Effect of paternal age in achondroplasia, thanatophoric dysplasia, and osteogenesis imperfecta. American Journal of Medical Genetics1995;59(2):209‐17. ">Orioli 1995</a>). Parents with OI caused by collagen mutations have a dominant disorder and 50% risk of having an affected child with each pregnancy. The majority of children with OI have inherited the disorder from a parent. <i>De novo</i> mutations account for approximately 35% of children with OI (<a href="./references#CD005088-bbs2-0053" title="Osteogenesis Imperfecta Foundation. Facts about Osteogenesis Imperfecta. www.oif.org(accessed August 2008). ">OIF 2008</a>). There are a number of less common causes of OI which are inherited as a recessive disorder in which case the risk is 25%. In general, these recessive forms of OI are more severe. </p> <p>Prior to the availability of molecular genetic analyses, four major phenotypic classifications of OI were identified based on Sillence criteria which includes inheritance mode, clinical presentation and radiographic findings (<a href="./references#CD005088-bbs2-0058" title="SillenceDO , SennA , DanksDM . Genetic heterogeneity in osteogenesis imperfecta. Journal of Medical Genetics1979;16(2):101‐16. ">Sillence 1979</a>). Further refinement of these classifications was made with molecular genetic analyses (<a href="./references#CD005088-bbs2-0027" title="ByersPH , WallisGA , WillingMC . Osteogenesis imperfecta: translation of mutation to phenotype. Journal of Medical Genetics1991;28(7):433‐42. ">Byers 1991</a>; <a href="./references#CD005088-bbs2-0028" title="ByersPH , SteinerRD . Osteogenesis imperfecta. Annual Review of Medicine1992;43:269‐82. ">Byers 1992</a>; <a href="./references#CD005088-bbs2-0043" title="GlorieuxFH , RauchF , PlotkinH , WardL , TraversR , RoughleyP , et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. Journal of Bone and Mineral Research2000;15(9):1650‐8. ">Glorieux 2000</a>; <a href="./references#CD005088-bbs2-0053" title="Osteogenesis Imperfecta Foundation. Facts about Osteogenesis Imperfecta. www.oif.org(accessed August 2008). ">OIF 2008</a>; <a href="./references#CD005088-bbs2-0060" title="SteinerRD , AdsitJ , BaselD . Gene Reviews; COL1A1/2‐Related Osteogenesis Imperfecta. http://www.ncbi.nlm.nih.gov/books/NBK1295/ (Initial Posting: January 28, 2005; Last Update: February 14, 2013). ">Steiner 2013</a>). However, recently, the classification has once again been reviewed as the clinical utility of multiple subtypes of OI based on molecular diagnoses was limited. A return to the more clinically useful classification scheme has been recommended as represented in <a href="#CD005088-tbl-0001">Table 1</a> (<a href="./references#CD005088-bbs2-0059" title="SillenceD . Osteogenesis Imperfecta. International committee for constitutional disorders of the skeleton. Sydney, 2012. ">Sillence 2012</a>). The diagnosis is made by a combination of history including family history, clinical examination, and radiographic findings with genetic and/or biochemical testing available for diagnostic confirmation. </p> <div class="table" id="CD005088-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Classification of osteogenesis imperfecta</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Syndrome names</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b># of subtypes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Subtypes and genetic basis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Previous type</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Classic Non‐deforming OI with Blue Sclerae</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ia ‐ With normal teeth or Opalescent Dentine caused by COL1A1</p> <p>Ib ‐ caused by COL1A2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Common variable OI with Normal Sclerae</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IVa ‐ caused by COL1A1</p> <p>IVb ‐ caused by COL1A2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OI with calcification in interosseous membranes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V ‐ caused by 5'UTR mutation in IFITM5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progressively Deforming OI with normal sclerae </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III ‐gene x</p> <p>III‐COL1A1 or COL1A2 inherited as autosomal dominant</p> <p>III ‐ CRTAP, P3H1/LEPRE1, PPIB, FKBP10, SERPINH1, SP7/OSX, SERPINF1 and BMP 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>International Nomenclature Committee for Constitutional Disorders of the Skeleton, Australia. </p> </div> </div> <p>In about 80% to 90% of individuals affected by OI, mutations in either of the genes encoding the pro‐α1 or pro‐α2 chains of type I collagen (COL1A1 or COL1A2) can be identified (<a href="./references#CD005088-bbs2-0030" title="Byers 2013 [perscomm] . OI [personal communication]. Email to: D Basel2013. ">Byers 2013</a>). Of those without collagen gene mutations, a number will have mutations in proteins involved in post‐translational modification or transport of type 1 collagen. These mutations tend to result in the progressively deforming type of OI (formerly Type III) or lethal OI (formerly Type II) and are inherited in an autosomal recessive manner. Genes involved include the following; CRTAP, P3H1/LEPRE1, PPIB, FKBP10, SERPINH1, SP7/OSX, SERPINF1, BMP1 and WNT1 (<a href="./references#CD005088-bbs2-0023" title="AlanayY , AvayganH , CamachoN , UtineGE , BodurogluK , AktasD , et al. Mutations in the gene encoding the RER protein FKBP65 cause autosomal‐recessive osteogenesis imperfecta. American Journal of Human Genetics2010;86(4):551‐9. ">Alanay 2010</a>; <a href="./references#CD005088-bbs2-0024" title="BarnesAM , ChangW , MorelloR , CabralWA , WeisMA , EyreDR , et al. Deficiency of cartilage‐associated protein in recessive lethal osteogenesis imperfecta. New England Journal of Medicine2006;355(26):2757‐64. ">Barnes 2006</a>; <a href="./references#CD005088-bbs2-0025" title="BeckerJ , SemlerO , GilissenC , LiY , BolzHJ , GiuntaC , et al. Exome sequencing identifies truncating mutations in human SERPINF1 in autosomal‐recessive osteogenesis imperfecta. American Journal of Human Genetics2011;88(3):362‐71. ">Becker 2011</a>; <a href="./references#CD005088-bbs2-0031" title="CabralWA , ChangW , BarnesAM , WeisM , ScottMA , LeikinS , et al. Prolyl 3‐hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nature Genetics2007;39(3):359‐65. ">Cabral 2007</a>; <a href="./references#CD005088-bbs2-0034" title="ChoTJ , LeeKE , LeeSK , SongSJ , KimKJ , JeonD , et al. A Single Recurrent Mutation in the 5'‐UTR of IFITM5 Causes Osteogenesis Imperfecta Type V. American Journal of Human Genetics2012;91(2):343‐8. ">Cho 2012</a>; <a href="./references#CD005088-bbs2-0035" title="ChristiansenHE , SchwarzeU , PyottSM , AlSwaidA , Al BalwiM , AlrasheedS , et al. Homozygosity for a missense mutation in SERPINH1, which encodes the collagen chaperone protein HSP47, results in severe recessive osteogenesis imperfecta. American Journal of Human Genetics2010;86(3):389‐98. ">Christiansen 2010</a>; <a href="./references#CD005088-bbs2-0050" title="LapunzinaP , AglanM , TemtamyS , Caparros‐MartinJA , ValenciaM , LetonR , et al. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. American Journal of Human Genetics2010;87(1):110‐4. ">Lapunzina 2010</a>; <a href="./references#CD005088-bbs2-0052" title="Martínez‐GlezV , ValenciaM , Caparrós‐MartínJA , AglanM , TemtamyS , TenorioJ , et al. Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta. Human Mutation2012;33(2):343‐50. ">Martinez‐Glez 2012</a>; <a href="./references#CD005088-bbs2-0055" title="PyottSM , TranTT , LeistritzDF , PepinMG , MendelsohnNJ , TemmeRT , et al. WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta. American Journal of Human Genetics2013;92(4):590‐7. ">Pyott 2013</a><a href="./references#CD005088-bbs2-0062" title="vanDijkFS , NesbittIM , ZwikstraEH , NikkelsPGJ , PiersmaSR , FratantoniSA , et al. PPIB mutations cause severe osteogenesis imperfecta. American Journal of Human Genetics2009;85(4):521‐7. ">Van Dijk 2009</a>). The subtype of OI associated with interosseous calcification and hypertrophic callus and inherited in an autosomal dominant manner was recently identified to be caused by a 5'UTR mutation of the IFITM5 gene (<a href="./references#CD005088-bbs2-0057" title="SemlerO , GarbesL , KeuppK , SwanD , ZimmermannK , BeckerJ , et al. A Mutation in the 5'‐UTR of IFITM5 Creates an In‐Frame Start Codon and Causes Autosomal‐Dominant Osteogenesis Imperfecta Type V with Hyperplastic Callus. American Journal of Human Genetics2012;91(2):349‐57. ">Semler 2012</a>). </p> </section> <section id="CD005088-sec-0024"> <h3 class="title" id="CD005088-sec-0024">Description of the intervention</h3> <p>There is no cure for OI and therapy is largely supportive at present. Therapy is varied and individualized depending upon OI severity, degree of impairment and age of the individual. Orthopedic management is paramount; surgical intervention or bracing of lower limbs, or both, is often required. Physical and occupational therapy are mainstays of therapy. Pharmacologic agents including growth hormone, calcitonin, parathyroid hormone, sodium fluoride, and vitamins have been administered in attempts to reduce fractures and deformities in OI. Oral and intravenous (IV) bisphosphonates are currently the most promising pharmacologic therapy and are routinely used for OI, since clinical trials of these agents have consistently shown improvements in bone mineral density (BMD) in people with OI. A prior version of this review and other systematic reviews have since found consistent improvements of BMD in people with OI who are treated with various bisphosphonates (<a href="./references#CD005088-bbs2-0033" title="CastilloH ,  Samson‐FangL ,  American Academy for Cerebral Palsy and Developmental Medicine Treatment Outcomes Committee Review Panel. Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Developmental Medicine and Child Neurology2009;51(1):17‐29. ">Castillo 2009</a>). Some trials also show fracture risk reduction and growth enhancement. </p> </section> <section id="CD005088-sec-0025"> <h3 class="title" id="CD005088-sec-0025">How the intervention might work</h3> <p>Bisphosphonates act by inactivating osteoclasts, the cells that break down bone tissue, thereby inhibiting bone resorption (<a href="./references#CD005088-bbs2-0041" title="FisherJE , RogersMJ , HalasyJM , LuckmanSP , HughesDE , MasarachiaPJ , et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro [abstract]. Proceedings of the National Academy of Sciences of the United States of America1999;96:133‐8. ">Fisher 1999</a>). There are two different types of bisphosphonates, nitrogenous and non‐nitrogenous. Nitrogenous bisphosphonates disrupt osteoclast formation, survival and cytoskeletal dynamics. Non‐nitrogenous bisphosphonates initiate osteoclast apoptosis. The bisphosphonates vary in their efficacy and absorption when taken orally, making direct comparison challenging. An additional table lists the currently available bisphosphonates (<a href="#CD005088-tbl-0002">Table 2</a>). </p> <div class="table" id="CD005088-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Current bisphosphonates</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mechanism of action</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Route of administration</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alendronate* (Fosamax)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate (Bonefos)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral, IV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Etidronate (Didronel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate (Boniva)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neridronate*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olpadronate*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral, IV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate* (Aredia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risendronate (Actonel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiludronate (Skelid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zolendronate (Zometa, Reclast)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Nitrogenous bisphosphonates disrupt osteoclast formation, survival and cytoskeletal dynamics. They contain nitrogen (a colourless tasteless odourless element that as a diatomic gas is relatively inert and constitutes 78% of the atmosphere and that is a constituent of organic compounds found in all living tissues). </p> <p>Non‐nitrogenous bisphosphonates initiate osteoclast apoptosis.</p> <p>IV: intravenous</p> </div> </div> <p>Bisphosphonates are widely used in post‐menopausal women to treat osteoporosis where they have been shown to increase bone density, decrease bone turnover (<a href="./references#CD005088-bbs2-0056" title="ReidIR , BrownJP , BurckhardtP , HorowitzZ , RichardsonP , TrechselU , et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New England Journal of Medicine2002;346(9):653‐61. ">Reid 2002</a>) and reduce fractures (<a href="./references#CD005088-bbs2-0026" title="BlackDM , CummingsSR , KarpfDB , CauleyJA , ThompsonDE , NevittMC , et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet1996;348(9041):1535‐41. ">Black 1996</a>). Although increases in BMD are not expected to alter the underlying defective Type I collagen in OI, it is anticipated that increased BMD might lead to decreased fracture rates analogous to bisphosphonate therapy in post‐menopausal women with osteoporosis (<a href="./references#CD005088-bbs2-0056" title="ReidIR , BrownJP , BurckhardtP , HorowitzZ , RichardsonP , TrechselU , et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New England Journal of Medicine2002;346(9):653‐61. ">Reid 2002</a>). Animal models give reason for optimism as increases in BMD in a mouse model of OI are accompanied by decreases in fracture rate (<a href="./references#CD005088-bbs2-0032" title="CamachoNP , RaggioCL , DotySB , RootL , ZraickV , IlgWA , et al. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcified Tissue International2001;69(2):94‐101. ">Camacho 2001</a>). Still, caution is advised, since the biology of OI differs from osteoporosis and improving bone density without altering resiliency may not lead to desired functional improvements (<a href="./references#CD005088-bbs2-0051" title="MariniJC . Do bisphosphonates make children's bones better or brittle?. New England Journal of Medicine2003;349(5):423‐6. ">Marini 2003</a>). A report of bisphosphonate‐induced osteopetrosis validates these concerns (<a href="./references#CD005088-bbs2-0063" title="WhyteMP , WenkertD , ClementsKL , McAlisterWH , MummS . Bisphosphonate‐induced osteopetrosis. New England Journal of Medicine2003;349(5):457‐63. ">Whyte 2003</a>). </p> </section> <section id="CD005088-sec-0026"> <h3 class="title" id="CD005088-sec-0026">Why it is important to do this review</h3> <p>There is currently no consensus on the effectiveness and safety of these agents in the treatment of OI. Optimal timing of treatment in both children and adults remains undefined, as does dose and duration of treatment. Additionally, it is not fully understood whether fracture healing or post‐surgical healing (or both) in people with OI will be impacted by bisphosphonate therapy. The optimal duration of bisphosphonate use is unclear even in post‐menopausal women (<a href="./references#CD005088-bbs2-0040" title="Food , Drug Administration(FDA) . Background document for meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM270958.pdf (accessed 07 March 2013). ">FDA 2011</a>). Emerging data from clinical trials and observational studies support an association between bisphosphonate use and atypical subtrochanteric femur fractures. These observations prompted the FDA to issue a warning regarding this possible adverse event (<a href="./references#CD005088-bbs2-0039" title="ErvitiJ , AlonsoA , OlivaB , GorrichoJ , LópezA , TimonerJ , et al. Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case–control study. http://bmjopen.bmj.com/content/3/1/e002091 (accessed 06 February 2013). ">Erviti 2013</a>). One of the authors (RS) observed such a complication in a teenage patient treated with alendronate. </p> <p>Children's natural proclivity towards increased BMD and growth, coupled with the tendency for decreased fractures with advancing age in children with OI, make data comparison between adults and children difficult. Large, multicentre, randomised, placebo‐controlled trials to better assess the specific effects of bisphosphonate therapy for OI are still indicated. The goals for use of pharmacologic agents in OI include increased bone density as measured by dual‐energy X‐ray absorptiometry (DEXA), decreased fracture incidence, lessening of deformity, reduced pain, and improved growth and mobility. </p> <p>This is an update of a previously published Cochrane Review (<a href="./references#CD005088-bbs2-0065" title="DwanK , PhillipiCA , SteinerRD , BaselD . Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD005088.pub3] ">Dwan 2014</a>; <a href="./references#CD005088-bbs2-0066" title="PhillipiCA , RemmingtonT , SteinerRD . Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD005088.pub2] ">Phillipi 2008</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005088-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005088-sec-0027"></div> <p>To assess the effectiveness and safety of bisphosphonates in increasing BMD, reducing fractures and improving clinical function in people with OI. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005088-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005088-sec-0028"></div> <section id="CD005088-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005088-sec-0030"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) and quasi‐randomised trials, published or unpublished.</p> </section> <section id="CD005088-sec-0031"> <h4 class="title">Types of participants</h4> <p>Children (defined as age 0 to 18 years) and adults with OI diagnosed using accepted diagnostic criteria, based on clinical or laboratory findings, or both. Individuals affected with all types of OI are included in this review. </p> </section> <section id="CD005088-sec-0032"> <h4 class="title">Types of interventions</h4> <p>Bisphosphonates to improve BMD in OI compared to placebo, no treatment control group, or comparator interventions, such as sodium fluoride; testosterone; vitamin C; vitamin D; flavonoids; calcitonin; growth hormone; parathyroid hormone; and different formulations or treatment regimens of bisphosphonates. </p> </section> <section id="CD005088-sec-0033"> <h4 class="title">Types of outcome measures</h4> <section id="CD005088-sec-0034"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD005088-list-0001"> <li> <p>Fracture reduction</p> <ol id="CD005088-list-0002"> <li> <p>numbers of breaks</p> </li> <li> <p>frequency of breaks (rates)</p> </li> </ol> </li> <li> <p>Change in BMD as assessed by DEXA</p> </li> </ol> </p> </section> <section id="CD005088-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD005088-list-0003"> <li> <p>Change in biochemical markers of bone and mineral metabolism (e.g. bone alkaline phosphatase measurements) </p> </li> <li> <p>Growth (z scores; vertebral heights)</p> </li> <li> <p>Bone pain (as assessed by self‐reported questionnaires of pain and analgesic use)</p> </li> <li> <p>Quality of life (e.g. functional changes in mobility, strength, well‐being and completion of activities of daily living (ADLs)) </p> </li> <li> <p>Lung function (e.g. pulmonary function testing)</p> </li> </ol> </p> <p>Outcome data were grouped at six months and then annually. If outcome data had been recorded at other time periods, consideration was given to examining these as well. </p> </section> </section> </section> <section id="CD005088-sec-0036"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005088-sec-0037"> <h4 class="title">Electronic searches</h4> <p>We searched the Cystic Fibrosis and Genetic Disorders Group's Inborn Errors of Metabolism Trials Register using the term: osteogenesis imperfecta. </p> <p>The Inborn Errors of Metabolism Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library), weekly searches of MEDLINE and the prospective handsearching of one journal ‐ <i>Journal of Inherited Metabolic Disease</i>. Unpublished work was identified by searching through the abstract books of the Society for the Study of Inborn Errors of Metabolism conference and the SHS Inborn Error Review Series. For full details of all searching activities for the register, please see the relevant section of the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/CF/frame.html" target="_blank">Cochrane Cystic Fibrosis and Genetic Disorders Group Module</a>. </p> <p>We have run searches of PubMed and Ovid MEDLINE from 1966 to June 2016. The search strategies are listed in the additional tables (<a href="#CD005088-tbl-0003">Table 3</a>; <a href="#CD005088-tbl-0004">Table 4</a>). </p> <div class="table" id="CD005088-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Search strategy ‐ PubMed 1996 to June 2016</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MESH terms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. osteogenesis imperfecta (827)<br/> 2. randomised controlled trial or Randomized Controlled Trials (49443)<br/> 3. 1 and 2 (4)<br/> 4. from 4 keep (2) </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD005088-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Search strategy ‐ Ovid MEDLINE 1996 to June 2016</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Search terms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. osteogenesis imperfecta (163)<br/> 2. randomised controlled trial (11846)<br/> 3. Randomized Controlled Trials (11906)<br/> 4. Combine 1, 2, 3 (7)<br/> 5. From 7 keep 2 (2) </p> </td> </tr> </tbody> </table> </div> <p>Date of the most recent search of the Group's Cystic Fibrosis and Genetic Disorders Group Inborn Errors of Metabolism Trials Register: 28 April 2016. </p> </section> <section id="CD005088-sec-0038"> <h4 class="title">Searching other resources</h4> <p>The major conference proceedings from the Osteogenesis Imperfecta Foundation national conference, 1995 to March 2005, and the American Society for Bone and Mineral Research annual meeting proceedings, 1996 to March 2005, were also hand searched in order to identify pertinent unpublished work. In addition, the authors contacted the pharmaceutical companies, who manufacture bisphosphonates (November 2004), for information on any relevant RCTs, but only one manufacturer responded. The data from the Novartis study concluded on 03 June 2008 are included in this review. </p> </section> </section> <section id="CD005088-sec-0039"> <h3 class="title" id="CD005088-sec-0039">Data collection and analysis</h3> <section id="CD005088-sec-0040"> <h4 class="title">Selection of studies</h4> <p>Two authors (CP and RS, or CP and DB) read the papers identified by the review search strategy for relevancy and then assessed the trials for inclusion in the review based on the criteria outlined above. They identified important comparisons within each class (e.g. oral versus IV bisphosphonates). If disagreement arose on the suitability of a trial for inclusion in the review or its quality, they reached a consensus by discussion. </p> </section> <section id="CD005088-sec-0041"> <h4 class="title">Data extraction and management</h4> <p>Two authors (CP and KD) independently extracted data using a structured form including date of publication, participant characteristics (especially demographics and type of OI), setting, detailed nature of intervention and control or, comparator, detailed nature of outcomes (i.e. bone density by DEXA, fractures, linear growth, bone turnover markers, bone pain and functional assessments). </p> </section> <section id="CD005088-sec-0042"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Previous versions of this review assessed the methodological quality of included studies based on the methods described by Jüni (<a href="./references#CD005088-bbs2-0048" title="JüniT , Altman , DG , EggerM . Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ2001;323(7303):42‐6. ">Jüni 2001</a>). </p> <p>This version of the review has used the Cochrane risk of bias assessment as described in the <i>Cochrane Hadbook for Systematic Reviews of Interventions 5.1</i> (<a href="./references#CD005088-bbs2-0046" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). Two authors (CP and KD) evaluated the included studies independently for the domains listed below as 'low risk', 'high risk' or 'unclear risk' of bias and resolved any disagreement by discussion. </p> <p> <ol id="CD005088-list-0004"> <li> <p>Random sequence generation</p> </li> <li> <p>Concealment of allocation</p> </li> <li> <p>Blinding of participants, personnel, outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective reporting</p> </li> <li> <p>Other potential sources of bias</p> </li> </ol> </p> </section> <section id="CD005088-sec-0043"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcome measures (fracture reduction) the authors collected data on the number of participants for each outcome event and allocated treatment group. The authors calculated a pooled estimate of the treatment effect for each outcome across trials using risk ratios (RR) and 95% confidence intervals (CIs) where appropriate. </p> <p>For continuous outcomes (change in BMD, change in biochemical markers of bone and mineral metabolism, growth, bone pain, quality of life, lung function) the authors recorded either the mean change from baseline for each group or mean post‐treatment or intervention values and standard deviation (SD) or standard error (SE) for each group. The authors calculated a pooled estimate of treatment effect by calculating the mean difference (MD) and 95% CIs. </p> </section> <section id="CD005088-sec-0044"> <h4 class="title">Unit of analysis issues</h4> <p>The authors included one cross‐over trial in the review and treated the data from this trial as parallel data; i.e. as if the results from the two periods were independent (<a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>), Elbourne reports that using this approach is conservative, due to the fact that it ignores the within‐patient correlation (<a href="./references#CD005088-bbs2-0038" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). </p> <p>For count data (number of fractures) the authors calculated the relative rate from the information given in the published papers from three trials using Poisson regression (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>; <a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>). </p> </section> <section id="CD005088-sec-0045"> <h4 class="title">Dealing with missing data</h4> <p>When the original papers presented data in a graph form, the authors sometimes estimated values for use in the review (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>). They calculated SDs when investigators reported SEs of the mean data (<a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>). The investigators of the Adami and Gatti trials kindly provided unpublished data on BMD (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>). </p> </section> <section id="CD005088-sec-0046"> <h4 class="title">Assessment of heterogeneity</h4> <p>The authors will assess heterogeneity by visual inspection of the forest plots, Chi² test and I² statistic. The I² statistic describes the percentage of total variation across trials due to heterogeneity rather than chance (<a href="./references#CD005088-bbs2-0045" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). The values of I² lie between 0% and 100%, and a simplified categorization of heterogeneity that the authors plan to use is of low (I² value of 25%), moderate (I² value of 50%), and high (I² value of 75%) (<a href="./references#CD005088-bbs2-0045" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). </p> </section> <section id="CD005088-sec-0047"> <h4 class="title">Assessment of reporting biases</h4> <p>In future reports, the authors plan to create a funnel plot in order to assess publication bias. If the authors observe asymmetry, they will investigate other reasons for this. Heterogeneity and selective outcome reporting would be possible sources for this bias. </p> </section> <section id="CD005088-sec-0048"> <h4 class="title">Data synthesis</h4> <p>In this review the authors have analysed data using a fixed‐effects model. However, if in future updates, if they include a sufficient number of trials and find significant heterogeneity, they plan to use a random‐effects model of statistical analysis and investigate possible causes of heterogeneity further (see below). </p> <p>The authors used meta‐analytic methods such as the inverse variance method for continuous outcomes and the Mantel‐Haenszel method for categorical outcomes. </p> <p>Meta‐analysis of the available data was limited due to the different agents used (oral versus IV bisphosphonates), different outcome measures, different populations (adults versus children), different reporting indices (z score versus t score versus total BMD), and variable inclusion of a placebo or control group. </p> </section> <section id="CD005088-sec-0049"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where the authors find heterogeneity, and if they have sufficient trials included in a meta‐analysis (i.e. four or more), they will investigate the possible causes further. Proposed subgroup analyses are by age (adults versus child); type of OI; and severity of disease (mild or severe). </p> </section> <section id="CD005088-sec-0050"> <h4 class="title">Sensitivity analysis</h4> <p>When the authors include sufficient trials, they will perform a sensitivity analysis based on the overall risk of bias of the trials, including and excluding quasi‐randomized trials. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005088-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005088-sec-0051"></div> <section id="CD005088-sec-0052"> <h3 class="title">Description of studies</h3> <p>Please also refer to '<a href="#CD005088-tbl-0005">Table 5</a>' for further details. </p> <div class="table" id="CD005088-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Study comparison: outcome data reported by individual studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Biochemical markers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BMD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fracture incidence</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Growth</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone pain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease in bone‐specific alkaline phosphatase 20%, decrease 25% in serum sCTx, decrease 20% in urinary free‐deoxypyridinoline in IV Neridronate group vs placebo. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase spine BMD 3.0 +/‐ 4.6%, hip 4.3 +/‐ 3.9% vs no significant change placebo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14% decrease in rate of fracture.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At the end of the follow‐up period, both groups<br/> showed a decrease in the fracture rate (P = 0.025 and P = 0.048,<br/> respectively) but no information was given comparing the groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There<br/> was no significant change in height in both groups throughout<br/> the treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease in bone‐specific alkaline phosphatase 1%, decrease 21% serum NTx over 2‐year trial period (grouped data). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lumbar spine BMD increased significantly only in the 2 mg/kg/wk group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall reduction in non‐vertebral fracture incidence in all groups during trial as compared to two years prior. Dose groups did not differ. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups in height z scores.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups in pain scores.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups in grip strength or self reported function.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The mean values for serum 25‐hydroxyvitamin D and intact parathyroid hormone were within normal ranges,<br/> and the changes from baseline were small at all time‐points<br/> for both treatment groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lumbar spine BMD increased significantly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>significant decrease in risk of recurrent clinical fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups in height z scores.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no difference in pain scales between the groups and the data was not shown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease in bone resorption markers (collagen peptides, osteocalcin) at one year. Alkaline phosphatase unchanged. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase spine BMD. Increase femur BMD. Effects seen primarily in first year of therapy.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in vertebral or peripheral fracture rate. Not adequately powered.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in pain except an increase with alendronate at 36 month time point.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease in alkaline phosphatase and bone alkaline phosphatase; decrease in urine NTX/Cr. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase BMD, BMC and area z scores in both oral and IV therapy.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased fracture incidence with time when both groups are combined.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase height and length combined group z scores compared to normal children.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant decrease in alkaline phosphatase from baseline. Groups did not differ.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase spine BMD in first 12 months, then groups were no longer different. BMD continued to be different from baseline. Initial increase (first 12 months) in height/projected lumbar spine area, followed by no change at 12 ‐ 26 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relative risk reduction 0.36% (CI, 0.15 ‐ 0.87; P &lt; 0.02).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Initial increase (first 12 months) in height/projected lumbar spine area, followed by no change at 12 ‐ 26 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant change from baseline as measured at each infusion time.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase spine BMD in treatment group as compared to control group. Increases were seen in the first 12 months but no further increases were noted with extended therapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased upper extremity fractures in the first year of treatment with no further decrease in the second year. No change in fracture incidence of lower extremity long bone fracture in the first or second year. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Growth rates were unchanged.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in self‐reported pain scores.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in muscle strength or gross motor abilities.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The secondary endpoints of relative change from baseline in biomarkers of bone turnover (serum ƒÀ‐CTx, P1NP and BALP, in participants greater than or equal to 3 years of age) all had statistically significant greater reductions in the zoledronic acid group compared to the pamidronate group at both 6 and 12 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The primary analysis of the percentage change in LS BMD at month 12 relative to baseline in the ITT (LOCF) population demonstrated that zoledronic acid was not only non‐inferior, but superior, to pamidronate with an 8% greater increase in LS BMD and both 95% confidence intervals above zero </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups in fractures.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups in mean supine length, mean vertebral spine length and height. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistically significant differences were identified between treatment groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease collagen type‐1 N‐telopeptide in treatment group compared to placebo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase spine BMD in treatment group compared to placebo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No detectable difference in new fractures.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in height z scores.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in bone pain.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in grip force.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant change between groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase spine z score 1.67 SD vs no significant change placebo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31% decrease in rate of fracture.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant change.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference in mobility / ambulation; muscle strength or self care.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease in urinary NTX/Cr. No change in serum markers or other urinary markers of bone turnover. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase in BMD z score 0.89 with alendronate compared to ‐0.12 with placebo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐significant trend toward decreased fractures.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased height z scores (0.41 vs 0.11) when alendronate is compared to placebo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased pain scores and decreased use of analgesia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improved well being scores. Increase in self care. No change in mobility.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease in bone specific alkaline phosphatase and serum NTx in both groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase in LSB mass for both groups. Increased LSBMD in 12/mg/kg/yr group after adjustment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No differences in crush fractured vertebrae between groups. Improved crush fractures in all but one infant. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in length z scores between groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease in uNTx (62%) compared to placebo (32%).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase in LSBMD compared to placebo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in fractures.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in height z scores.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in bone pain.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in mobility.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>IV: intravenous<br/> NTX/Cr: N‐linked telopeptides/creatinine<br/> sCTx: serum cross‐laps<br/> vs: versus </p> </div> </div> <section id="CD005088-sec-0053"> <h4 class="title">Results of the search</h4> <p>Twenty‐one trials were identified and reviewed, of which 14 (including 819 participants) RCTs met the inclusion criteria (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>; <a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>; <a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>; <a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>; <a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>; <a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). </p> </section> <section id="CD005088-sec-0054"> <h4 class="title">Included studies</h4> <p>Six trials compared an oral bisphosphonate to placebo (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>), while three trials compared an IV bisphosphonate to placebo (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>; <a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>). One trial compared different doses of oral bisphosphonates (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>) and one trial compared different doses of IV bisphosphonates (<a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>). One trial compared oral to IV bisphosphonates (<a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>). Two trials compared different IV bisphosphonates (<a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>; <a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). </p> <p>Twelve trials enrolled 709 children, one of which included participants up to 19 years of age (<a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>), which we included as children (<a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>; <a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>; <a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>; <a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>; <a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>) and two trials enrolled 110 adults (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>).  </p> </section> <section id="CD005088-sec-0055"> <h4 class="title">Excluded studies</h4> <p>Eight trials were excluded from the review (<a href="./references#CD005088-bbs2-0015" title="AntoniazziF , BertoldoF , MottesM , ValliM , SirpresiS , ZamboniG , et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. Journal of Pediatrics1996;129(3):432‐9. ">Antoniazzi 1996</a>; <a href="./references#CD005088-bbs2-0016" title="AntoniazziF , ZamboniG , LauriolaS , DonadiL , AdamiS , TatoL . Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. Journal of Pediatrics2006;149(2):174‐9. ">Antoniazzi 2006</a>; <a href="./references#CD005088-bbs2-0017" title="AntoniazziF , MontiE , VenturiG , FranceschiR , DoroF , GattiD , et al. GH in combination with bisphosphonate treatment in osteogenesis imperfecta. European Journal of Endocrinology2010;163(3):479‐87. ">Antoniazzi 2010</a>; <a href="./references#CD005088-bbs2-0018" title="DiMeglioLA , FordL , McClintockC , PeacockM . Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone2004;35(5):1038‐45. ">DiMeglio 2004</a>; <a href="./references#CD005088-bbs2-0019" title="GerberLH , BinderH , BerryR , SiegelKL , KimH , WeintrobJ , et al. Effect of withdrawal of bracing in matched pairs of children with osteogenesis imperfecta. Archives of Physical Medicine and Rehabilitation1998;79(1):46‐51. ">Gerber 1998</a>; <a href="./references#CD005088-bbs2-0020" title="GrandaJL , FalvaKA , BulloughPG . Phyrophosphate levels and magnesium oxide therapy in osteogenesis imperfecta. Clinical Orthopaedics and Related Research1977;Jul‐Aug(216):228‐31. ">Granda 1977</a>; <a href="./references#CD005088-bbs2-0021" title="NCT00131469 . Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta (OI). http://clinicaltrials.gov/show/NCT00131469 (accessed 08 March 2013). [] NagamaniS , ShapiroJ , VeithS , WangY , LapidusJ , ReederJL , et al. Teriparatide, the first anabolic agent for treatment of osteogenesis imperfecta improves bone mineral density at the hip and spine: a randomized, blinded, placebo‐controlled trial [abstract]. Proceedings of the 63rd Annual Meeting of the American Society of Human Genetics; 2013 Oct 22‐26; Boston. Boston: American Society of Human Genetics, 2013:27. OrwollES , ShapiroJ , VeithS , WangY , LapidusJ , VanekC , et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. Journal of Clinical Investigation2014;124(2):491‐8. [CENTRAL: 977911; CRS: 5500050000000133; EMBASE: 2014112169; PUBMED: 24463451] ">Orwoll 2014</a>; <a href="./references#CD005088-bbs2-0022" title="WardLM , DenkerAE , PorrasA , ShugartsS , KlineW , TraversR , et al. Single‐dose pharmacokinetics and tolerability of alendronate 35‐ and 70‐milligram tablets in children and adolescents with osteogenesis imperfecta type I. Journal of Clinical Endocrinology and Metabolism2005;90(7):4051‐6. ">Ward 2005</a>). Four trials were not RCTs (<a href="./references#CD005088-bbs2-0015" title="AntoniazziF , BertoldoF , MottesM , ValliM , SirpresiS , ZamboniG , et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. Journal of Pediatrics1996;129(3):432‐9. ">Antoniazzi 1996</a>; <a href="./references#CD005088-bbs2-0016" title="AntoniazziF , ZamboniG , LauriolaS , DonadiL , AdamiS , TatoL . Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. Journal of Pediatrics2006;149(2):174‐9. ">Antoniazzi 2006</a>; <a href="./references#CD005088-bbs2-0018" title="DiMeglioLA , FordL , McClintockC , PeacockM . Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone2004;35(5):1038‐45. ">DiMeglio 2004</a>; <a href="./references#CD005088-bbs2-0022" title="WardLM , DenkerAE , PorrasA , ShugartsS , KlineW , TraversR , et al. Single‐dose pharmacokinetics and tolerability of alendronate 35‐ and 70‐milligram tablets in children and adolescents with osteogenesis imperfecta type I. Journal of Clinical Endocrinology and Metabolism2005;90(7):4051‐6. ">Ward 2005</a>). A further trial did not evaluate bisphosphonates but rather long‐leg braces (<a href="./references#CD005088-bbs2-0019" title="GerberLH , BinderH , BerryR , SiegelKL , KimH , WeintrobJ , et al. Effect of withdrawal of bracing in matched pairs of children with osteogenesis imperfecta. Archives of Physical Medicine and Rehabilitation1998;79(1):46‐51. ">Gerber 1998</a>). One trial studied pyrophosphate levels in OI disease severity rather than improvement in bone density or fracture reduction (<a href="./references#CD005088-bbs2-0020" title="GrandaJL , FalvaKA , BulloughPG . Phyrophosphate levels and magnesium oxide therapy in osteogenesis imperfecta. Clinical Orthopaedics and Related Research1977;Jul‐Aug(216):228‐31. ">Granda 1977</a>), and a further trial investigated response to growth hormone rather than bisphosphonates (<a href="./references#CD005088-bbs2-0017" title="AntoniazziF , MontiE , VenturiG , FranceschiR , DoroF , GattiD , et al. GH in combination with bisphosphonate treatment in osteogenesis imperfecta. European Journal of Endocrinology2010;163(3):479‐87. ">Antoniazzi 2010</a>). The eighth trial investigated teriparatide, a parathyroid hormone analogue and not a bisphosphonates (<a href="./references#CD005088-bbs2-0021" title="NCT00131469 . Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta (OI). http://clinicaltrials.gov/show/NCT00131469 (accessed 08 March 2013). [] NagamaniS , ShapiroJ , VeithS , WangY , LapidusJ , ReederJL , et al. Teriparatide, the first anabolic agent for treatment of osteogenesis imperfecta improves bone mineral density at the hip and spine: a randomized, blinded, placebo‐controlled trial [abstract]. Proceedings of the 63rd Annual Meeting of the American Society of Human Genetics; 2013 Oct 22‐26; Boston. Boston: American Society of Human Genetics, 2013:27. OrwollES , ShapiroJ , VeithS , WangY , LapidusJ , VanekC , et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. Journal of Clinical Investigation2014;124(2):491‐8. [CENTRAL: 977911; CRS: 5500050000000133; EMBASE: 2014112169; PUBMED: 24463451] ">Orwoll 2014</a>). </p> </section> </section> <section id="CD005088-sec-0056"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias has been assessed for this update and information is included below and in <a href="./references#CD005088-sec-0142" title="">Characteristics of included studies</a> tables. </p> <section id="CD005088-sec-0057"> <h4 class="title">Allocation</h4> <section id="CD005088-sec-0058"> <h5 class="title">Generation of the allocation sequence</h5> <p>Six trials were described as randomised, by computer‐generated random numbers and were deemed to have a low risk of bias (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>; <a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>; <a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>). One further trial used an interactive voice response system and was deemed to have a low risk of bias (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>). </p> <p>Six trials were described as randomised, although no information on the randomised procedures used was given and the trials are therefore at an unclear risk of bias (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>; <a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). Similarly, the Gatti trial was described as a RCT but the method was not fully described and participants were assigned according to OI type to either an active or control group (unclear risk of bias) (<a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>). </p> </section> <section id="CD005088-sec-0059"> <h5 class="title">Concealment of allocation</h5> <p>For eight trials, the method of allocation concealment was not stated and therefore were at an unclear risk of bias (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>; <a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>; <a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). </p> <p>For the Sakkers trial, generation of the randomisation sequence was done independently of the researchers by an outside group, therefore concealment was deemed at low risk of bias (<a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>). Similarly, for the Seikaly trial allocation was concealed by a pharmacist at the institution and was found to be at a low risk of bias (<a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>). For the Cheverel trial, allocation was concealed by giving the randomised list to the researchers who then assigned each new trial participant the subsequent number on the list (low risk of bias) (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>). For the DiMeglio trial, allocation concealment was ensured by a clinic nurse who assigned treatment (low risk of bias) (<a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>). Two trials used allocation by a remote telephone system randomisation and was at a low risk of bias (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>). </p> </section> </section> <section id="CD005088-sec-0060"> <h4 class="title">Blinding</h4> <p>Six trials were described as double blinded and therefore are at a low risk of bias (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>). </p> <p>The Adami trial stated that "prevalent vertebral fractures were identified and graded blindly by a semi quantitative scale", so was therefore at a low risk of bias for outcome assessors (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>). The Letocha trial was described as unblinded but the investigators were stated as blinded to vertebral area/compression (<a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>) so outcome assessors were at a low risk of bias. The Gatti trial was not described as blinded and is therefore at an unclear risk of bias (<a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>). </p> <p>Two trials were open label and therefore at a high risk of bias (<a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>; <a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>). One trial was open label but the outcome assessors were blind to treatment allocation therefore this trial was deemed at a low risk of bias (<a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). One trial had carers, participants and outcome assessors blinded and was therefore at low risk of bias (<a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>). Details of blinding were not stated in one trial and was therefore at an unclear risk of bias (<a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>). </p> </section> <section id="CD005088-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>For the Sakkers trial, an intention‐to‐treat analysis was undertaken. Two participants (one placebo and one treatment) withdrew from the trial but were accounted for in the final analysis and is at low risk of bias (<a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>). It was also reported that intention‐to‐treat analyses were performed in the Cheverel trial, and dropouts were described, therefore the trial is at a low risk of bias (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>). </p> <p>In the Adami trial, per protocol analyses were performed; although intention‐to‐treat analyses were planned, they were not applied as all participants completed the treatment follow up, indicating a low risk of bias (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>). Similarly, in the Gatti trial, intention‐to‐treat analyses were planned but not applied as all participants completed the treatment follow up (<a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>). </p> <p>In the Letocha trial a per protocol and repeated‐measures model was used but its is not clear if all participants completed the trial, so is therefore at an unclear risk of bias (<a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>). </p> <p>For the Seikaly trial it is unclear whether intention‐to‐treat analyses were performed introducing potential attrition bias, therefore this trial is at an unclear risk of bias (<a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>). </p> <p>The type of analysis performed is not stated for the DiMeglio trial, although changes in group assignment were made when participants had difficulty tolerating the assigned regimen (<a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>). Loss to follow up for each group is reported therefore the trial is at low risk of bias. </p> <p>One trial did not provide any information on the reasons that participants dropped out of the trial and they did not state if an intention‐to‐treat analysis was used (<a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>). This trial was therefore deemed at an unclear risk of bias. </p> <p>For six trials all dropouts were reported indicating a low risk of bias (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>; <a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). </p> </section> <section id="CD005088-sec-0062"> <h4 class="title">Selective reporting</h4> <p>Eight trials were classified as having a low risk of bias as outcomes stated in the methods sections were reported (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>; <a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>; <a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). However, we had no access to protocols for this judgement, although trial registry information was available for one trial (<a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). Five trials were judged as having high risk of bias as outcomes were only reported as non‐significant and no further data were reported (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>; <a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>). One trial was classed as having an unclear risk of bias as decreased fracture rate was not fully reported (<a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>). </p> </section> <section id="CD005088-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>Some trials employed retrospective methods to assess fracture rates and may be subject to recall bias (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>; <a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>). The natural proclivity towards reduced fractures and growth with age makes comparison difficult if adjusted scoring such as z scores are not used by researchers. </p> </section> </section> <section id="CD005088-sec-0064"> <h3 class="title" id="CD005088-sec-0064">Effects of interventions</h3> <p>As mentioned above, data were sometimes estimated when presented in graph form (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>). Standard deviations were calculated when SEs of the mean data were reported by the trial investigators (<a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>). For the Adami and Gatti trials, the intervention groups each received treatment for 24 and 36 months respectively, and the control groups also began active therapy at 12 months for the remainder of each trial (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>). Data are reported in this review at the 6 and 12 month time‐points for both trials where there is a comparison between intervention versus control (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>). </p> <p>One cross‐over trial was included in the review, data from this trial were treated as parallel data (<a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>). For count data (number of fractures), the relative rate was calculated from the information given in the published papers or received from authors from five trials using Poisson regression (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>; <a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>). </p> <section id="CD005088-sec-0065"> <h4 class="title">Oral bisphosphonates compared to placebo or no treatment control group</h4> <p>Six trials were included in this comparison (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>). </p> <section id="CD005088-sec-0066"> <h5 class="title">Primary outcomes</h5> <section id="CD005088-sec-0067"> <h6 class="title">1. Fracture incidence</h6> <p>Each of the six trials reported on this outcome (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>). The Sakkers trial reported a 31% reduction in relative risk for fracture after treatment with oral olpadronate, and when analysed in the review this produced a hazard ratio of 0.69 (95% CI 0.52 to 0.91) (<a href="./references#CD005088-fig-0001" title="">Analysis 1.1</a> ‐ as reported in the paper) and a statistically significantly decreased fracture number, relative rate (RR) 0.40 (95% CI 0.24 to 0.69) (<a href="./references#CD005088-fig-0002" title="">Analysis 1.2</a>) (<a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>). The Bishop trial also reported risk of recurrent clinical fracture and when analysed in the review this produced a HR of 0.58 (95% CI: 0.37 to 0.92) (P = 0.0416) at 12 months, which was statistically significant in favour of oral risendronate (<a href="./references#CD005088-fig-0001" title="">Analysis 1.1</a>). The Bishop trial also reported statistically significant differences in clinical non‐vertebral (29 out of 92 versus 24 out of 49, P = 0.0446) and long‐bone fractures (18 out of 94 versus 17/ out of 49) and time to first fracture, HR 0.53 (95% CI 0.31 to 0.92) (P = 0.0337) (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>). </p> <p>Seikaly noted "a tendency to decrease the frequency of bone fractures" with alendronate versus placebo that did not reach significance (<a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>). Data cannot be entered into the meta‐analysis for this cross‐over trial as the total number of fractures (and not number of participants with one fracture or more) were reported across treatment groups. Three trials (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>) also showed no statistically significant difference in the number of people with at least one fracture with bisphosphonates compared to placebo, two trials at 24 months, RR 1.05 (95% CI 0.82 to 1.35) (<a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>) and one at 36 months, RR 0.97 (95% CI 0.48 to 1.95) (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>) (<a href="./references#CD005088-fig-0003" title="">Analysis 1.3</a>). However, Chevrel was not adequately powered to detect differences in fracture rate (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>). Rauch reported 11 fractures from seven of the 13 participants (0 to 2 per participant) in the risedronate group and 11 fractures from six of the 13 participants (0 to 4 per participant) in the placebo group (<a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>). </p> </section> <section id="CD005088-sec-0068"> <h6 class="title">2. Change in BMD as assessed by DEXA</h6> <section id="CD005088-sec-0069"> <p><b>a. Mean per cent change in spine BMD</b></p> <p>Each of the six trials reported on this outcome (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>). For the Sakker trial, data are not available in an appropriate form to be entered into the meta‐analyses (<a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>). Data for this trial were presented as within‐group changes (not presented in this review) showing statistically significant improvements in the bisphosphonates group and statistically non‐significant changes in the placebo group (<a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>). One trial found a statistically significantly increase in lumbar spine density z scores at six months, in favour of oral bisphosphonates, MD 0.39 (95% CI 0.28, 0.50) (<a href="./references#CD005088-fig-0004" title="">Analysis 1.4</a>) (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>). Two trials found a statistically significantly increased lumbar spine density z scores at 12 months, in favour of oral bisphosphonates, MD 0.51 (95%CI 0.35 to 0.68) (<a href="./references#CD005088-fig-0004" title="">Analysis 1.4</a>) (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>). Two trials reported a significant change in lumbar spine area BMD z score at 24 months, MD 0.99 (95% CI 0.70, 1.28) in favour of oral bisphosphonates (<a href="./references#CD005088-fig-0004" title="">Analysis 1.4</a>) (<a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>). </p> <p>Chevrel reported a significant increase in lumbar spine BMD throughout the three years of the trial (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>). It was reported that the increase was much greater after the first 12 months, although this continued, without reaching a plateau to the end of treatment at 36 months; for lumbar spine at 12 months, MD 7.00 (95% CI 3.87 to 10.13) and at 36 months, MD 9.40 (95% CI 5.44 to 13.36) (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>) (<a href="./references#CD005088-fig-0005" title="">Analysis 1.5</a>). Three studies reported a significant difference at two years, MD 17.31 (95% CI 5.01 to 29.62) although there was a considerable amount of heterogeneity (I² = 77%) (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>) (<a href="./references#CD005088-fig-0005" title="">Analysis 1.5</a>). </p> </section> <section id="CD005088-sec-0070"> <p><b>b. Mean per cent change in total femur BMD</b></p> <p>One trial reported on this outcome (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>). The mean per cent change in total femur BMD were reported by Chevrel at 36 months, the increase in the alendronate group was statistically significantly greater than that in the placebo group; total femur BMD, MD 3.00 (95% CI 2.73 to 3.27) (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>) (<a href="./references#CD005088-fig-0006" title="">Analysis 1.6</a>). </p> </section> </section> </section> <section id="CD005088-sec-0071"> <h5 class="title">Secondary Outcomes</h5> <section id="CD005088-sec-0072"> <h6 class="title">1. Change in biochemical markers of bone and mineral metabolism and bone histology</h6> <p>The varied markers chosen for study in the included trials we reviewed prohibited direct comparison, but a narrative description of the findings are presented. </p> <p>Each of the six trials reported on this outcome (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>; <a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>). Sakkers reported (in narrative format only) no statistically significant change in urine or serum markers between the olpadronate and placebo groups (<a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>). Seikaly also found no change in serum or urinary markers of bone turnover between the alendronate and placebo groups.  However, since data for this cross‐over trial were presented separately by treatment arm for each of the four arms of the trial, we were unable to analyse this as if it were a parallel trial as planned (<i>See</i>: <a href="#CD005088-sec-0044">Unit of analysis issues</a>) (<a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>). A decrease in some bone resorption markers (collagen peptides, osteocalcin) with alendronate administration was noted by Chevrel while alkaline phosphatase levels were unchanged (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>). In the Ward trial, no difference was found in serum alkaline phosphatase, but there was a difference in uNTx to creatinine ratio (<a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>). Rauch reported a difference in risedronate and placebo for serum NTX %, but no difference for alkaline phosphatase % and urine NTX/Cr % (<a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>). The Bishop trial reported normal and unchanged values for serum 25‐hydroxyvitamin D and intact parathyroid hormone at all time‐points for both treatment groups (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>). They additionally report statistically significant changes in both urine NTx/Cr and bone‐specific alkaline phosphatase at the six‐ and 12‐month time periods (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>). </p> </section> <section id="CD005088-sec-0073"> <h6 class="title">2. Growth</h6> <p>Five trials reported on this outcome (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>). Sakkers narratively reported no differences in seated height or radiographic assessments of lumbar vertebral height between olpadronate and placebo at 24‐months follow up (<a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>). Bishop and Seikaly found a statistically significant increase in height growth z scores in response to 12 months of alendronate therapy, MD 0.24 (95% CI 0.04 to 0.43) (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>), but Rauch and Ward did not find a statistically significant difference at 24 months, MD 0.08 (95% CI ‐0.19 to 0.35) (<a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>) (<a href="./references#CD005088-fig-0007" title="">Analysis 1.7</a>). This outcome was not addressed in the remaining trial (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>). </p> </section> <section id="CD005088-sec-0074"> <h6 class="title">3. Bone pain</h6> <p>Five trials reported on this outcome (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>). For the alendronate group, statistically significant decreases in pain scores and analgesic use at 12 months were reported by Seikaly, MD ‐3.63 (95% CI ‐5.17 to ‐2.09) and MD ‐2.00 (95% CI ‐3.57 to ‐0.43), respectively (<a href="./references#CD005088-fig-0008" title="">Analysis 1.8</a>; <a href="./references#CD005088-fig-0009" title="">Analysis 1.9</a>) (<a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>). Here, the interaction of treatment and order were not statistically significant, indicating that differences found between alendronate and placebo were not explained by order of administration. At 24 months Ward reported a non‐significant difference (in favour of the alendronate group), MD ‐0.73 (95% CI ‐2.64, 1.18) (<a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>). The number of participants with bone pain was also reported as 37% (38 out of 102) in the alendronate group and 57% (17 out of 30) in the placebo group. Chevrel narratively reported that the pain score was similar in both groups from 0 to 30 months and reported end of trial data that showed an increase at 36 months with alendronate, MD 1.30 (95% CI 0.14 to 2.46) (<a href="./references#CD005088-fig-0008" title="">Analysis 1.8</a>) (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>). Rauch reported that the number of participants suffering from bone pain at the end of the trial was 31% (four out of 13) in both the risedronate group and the placebo group and the difference was not statistically significant (<a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>). Bishop did not identify a difference in pain scales between the groups and the data was not shown. However, they do report pain as an adverse events reported by at least 10% of participants in either group (pain in 14 out of 94 versus five out of 49 and pain in the arms and back in 20 out of 94 versus 14 out of 49) (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>). </p> <p>Bone pain was not evaluated by Sakkers (<a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>). </p> </section> <section id="CD005088-sec-0075"> <h6 class="title">4. Quality of life</h6> <p>Four of the included trials evaluated at least one quality of life outcome (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>). Seikaly reported a statistically significant increase in well‐being as assessed by scored participant recall, MD 3.19 (95% CI 2.25 to 4.13) (<a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>) (<a href="./references#CD005088-fig-0010" title="">Analysis 1.10</a>); improved self‐care skills or ADLs (assessed by Pediatric Evaluation of Disability Inventory (PEDI), a validated measurement tool) with alendronate versus placebo, MD 3.58 (95% CI 1.06 to 6.10) (<a href="./references#CD005088-fig-0011" title="">Analysis 1.11</a>); but no improvements in mobility as assessed by WeeFIM (a validated measurement tool for transfers, locomotion, access to stairs), MD 0.79 (95% CI ‐3.31 to 4.89) (<a href="./references#CD005088-fig-0012" title="">Analysis 1.12</a>). In contrast, Sakkers compared olpadronate to placebo and narratively reported that there were no changes in functional outcomes as assessed by PEDI, nor did the authors find changes in grip or hip flexor strength. Mobility as assessed by another validated scale (Bleck) was also not improved when compared to placebo controls (<a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>). These functional outcomes were not addressed in other included studies (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>). Chevrel was the only trial to assess hearing and did not find any difference (as assessed by Rinne testing %) with alendronate administration, MD ‐0.10 (95% CI ‐2.88 to 2.68) (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>) (<a href="./references#CD005088-fig-0013" title="">Analysis 1.13</a>). </p> <p>The Ward trial reported no change from baseline in self‐care, mobility and grip force at 24 months; self‐care, MD 2.01 (95% CI ‐1.31 to 5.33) (<a href="./references#CD005088-fig-0011" title="">Analysis 1.11</a>); and mobility, MD 1.50 (95% CI ‐4.55, 7.55) (<a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>) (<a href="./references#CD005088-fig-0012" title="">Analysis 1.12</a>). </p> <p>Two trials did not report on quality of life (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>). </p> </section> <section id="CD005088-sec-0076"> <h6 class="title">5. Lung function</h6> <p>None of the included trials reported on this outcome (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>). </p> </section> </section> </section> <section id="CD005088-sec-0077"> <h4 class="title">IV Bisphosphonates compared to placebo or no treatment control group</h4> <p>Three trials were included in this comparison (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>; <a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>). </p> <section id="CD005088-sec-0078"> <h5 class="title">Primary outcomes</h5> <section id="CD005088-sec-0079"> <h6 class="title">1. Fracture incidence</h6> <p>Each of the included trials reported on this outcome (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>; <a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>). For the Adami and Gatti trials, data on the number of participants with at least one fracture were obtained from the primary investigators. There was no statistically significant difference between the treatment and control groups, RR 0.56 (95% CI 0.30 to 1.06) (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>) (<a href="./references#CD005088-fig-0014" title="">Analysis 2.1</a>). Data were also obtained on the total number of fractures amongst participants for the treatment and control groups and these were one out of 31 and two out of 15 (respectively) for the Adami trial and 13 out of 42 and 18 out of 22 for the Gatti trial (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>). For the Letocha trial the incidence of fractures of the lower and upper extremities at 12 months did not change statistically significantly between the pamidronate and placebo groups from baseline, MD ‐0.11 (95% CI ‐0.96 to 0.74) (<a href="./references#CD005088-fig-0015" title="">Analysis 2.2</a>;); MD ‐0.22 (95% CI ‐0.67 to 0.23), respectively (<a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>) (<a href="./references#CD005088-fig-0016" title="">Analysis 2.3</a>). </p> </section> <section id="CD005088-sec-0080"> <h6 class="title">2. Change in BMD as assessed by DEXA</h6> <section id="CD005088-sec-0081"> <p><b>a. Mean per cent change in spine BMD</b></p> <p>Each of the included trials reported on this outcome (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>; <a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>). Adami reported BMD at six month intervals from six to 24 months. In this trial, the intervention group received neridronate for 24 months and the control group began therapy at 12 months which continued for 12 months. We therefore report data here for the six‐ and 12‐month time points to compare intervention versus no treatment (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>). When summary statistics from two studies were calculated, there was no statistically significant differences between treatment and control groups in spine BMD at six months, MD 9.96 (95% CI ‐2.51 to 22.43) (I² = 89%) and at 12 months, MD 14.68 (95% CI ‐6.08 to 35.45) (I² = 95%) (<a href="./references#CD005088-fig-0017" title="">Analysis 2.4</a>) (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>). However, it should be noted that the I² values are very large, representing a considerable amount of heterogeneity, I² = 89% and 95% respectively, although there are only two studies. Letocha investigated the mean per cent change in spine BMD z score and found statistically significant increases with IV pamidronate at six months, MD 21.59 (95% CI 5.79 to 37.39) and 12 months, MD 25.60 (95% CI 11.48 to 39.72) (<a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>) (<a href="./references#CD005088-fig-0018" title="">Analysis 2.5</a>). </p> </section> <section id="CD005088-sec-0082"> <p><b>b. Mean per cent change in hip BMD</b></p> <p>Two of the included trials reported on this outcome (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>). Adami and Gatti reported data on total hip BMD at six and 12 months. No statistically significant differences were noted when hip BMD data from these trials were combined, MD 6.16 (95% CI ‐3.57 to 15.90) and MD 11.27 (95% CI ‐3.69 to 26.22), respectively (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>) (<a href="./references#CD005088-fig-0019" title="">Analysis 2.6</a>). </p> <p>We note for both mean per cent change in spine and hip BMD for the Adami and Gatti trials that there are large differences in the SDs reported for each of these two trials and whilst clinically it is appropriate for these trials to be combined, we plan to investigate this heterogeneity further once more trials are included (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>). </p> </section> </section> </section> <section id="CD005088-sec-0083"> <h5 class="title">Secondary Outcomes</h5> <section id="CD005088-sec-0084"> <h6 class="title">1. Change in biochemical markers of bone and mineral metabolism and bone histology</h6> <p>Two trials reported on this outcome (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>). Information was provided narratively within the text for each trial. Adami reported a decrease in: bone specific alkaline phosphatase (BSAP); serum C‐telopeptide (sCTx); and urinary free‐deoxy pyridinoline (ufDPD) in the neridronate group (within group data not presented) (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>). In the Gatti trial, statistically significant decreases in alkaline phosphatase were found with IV administration of neridronate in children (<a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>). </p> </section> <section id="CD005088-sec-0085"> <h6 class="title">2. Growth</h6> <p>One trial reported on this outcome (<a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>). There were no statistically significant improvements in growth rate at 12 months, MD 1.07 (95% CI ‐2.24 to 4.38) (<a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>) (<a href="./references#CD005088-fig-0020" title="">Analysis 2.7</a>). Growth was not measured in the remaining trials (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>). </p> </section> <section id="CD005088-sec-0086"> <h6 class="title">3. Bone pain</h6> <p>One trial reported on this outcome (<a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>). No changes in self‐reported bone pain on a self‐evaluation four‐point scale were found by Letocha, MD ‐0.11 (95% CI ‐0.83 to 0.61) (<a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>) (<a href="./references#CD005088-fig-0021" title="">Analysis 2.8</a>). Bone pain was not addressed by the remaining two trials using IV bisphosphonates (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>). </p> </section> <section id="CD005088-sec-0087"> <h6 class="title">4. Quality of life</h6> <p>One trial reported on this outcome (<a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>). Letocha investigated muscle strength and gross motor function (using BAMF (Brief Assessment of Motor Function), a 10‐point gross motor assessment tool) (<a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>). No differences in muscle strength or functional mobility were noted between the IV pamidronate and control groups during treatment, MD ‐3.18 (95% CI ‐18.97 to 12.61) (<a href="./references#CD005088-fig-0022" title="">Analysis 2.9</a>); MD ‐0.80 (95% CI ‐2.42 to 0.82), respectively (<a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>) (<a href="./references#CD005088-fig-0023" title="">Analysis 2.10</a>). Outcomes reflecting quality of life were not evaluated or reported in the remaining IV bisphosphonates trials (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>). </p> </section> <section id="CD005088-sec-0088"> <h6 class="title">5. Lung function</h6> <p>None of the included trials reported on this outcome (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>; <a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>). </p> </section> </section> </section> <section id="CD005088-sec-0089"> <h4 class="title">Oral versus IV bisphosphonates</h4> <p>One trial was included in this comparison (<a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>). </p> <section id="CD005088-sec-0090"> <h5 class="title">Primary outcomes</h5> <section id="CD005088-sec-0091"> <h6 class="title">1. Fracture incidence</h6> <p>DiMeglio reported annualised fracture rates and found no difference between oral alendronate and IV pamidronate treatment groups, MD 0.50 (95% CI ‐0.64 to 1.64) (<a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>) (<a href="./references#CD005088-fig-0024" title="">Analysis 3.1</a>). </p> </section> <section id="CD005088-sec-0092"> <h6 class="title">2. Change in BMD as assessed by DEXA</h6> <p>DiMeglio did not find a difference in BMD when they compared oral to IV therapy at 12 months, MD 0.30 (95% CI ‐1.11 to 1.71) and 24 months, MD 0.20 (95% CI ‐1.32 to 1.72) (<a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>) (<a href="./references#CD005088-fig-0025" title="">Analysis 3.2</a>). </p> </section> </section> <section id="CD005088-sec-0093"> <h5 class="title">Secondary Outcomes</h5> <section id="CD005088-sec-0094"> <h6 class="title">1. Change in biochemical markers of bone and mineral metabolism and bone histology</h6> <p>DiMeglio reported that there were no statistically significant differences in response between the two treatment groups at four, 12, or 24 months (<a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>). Data were reported for the four‐ and 24‐month time‐periods for change in alkaline phosphonate (IU/L)) at four months, MD ‐12.00 (95% CI ‐86.09 to 62.09) and 12 months, MD ‐35.00 (95% CI ‐115.36 to 45.36) (<a href="./references#CD005088-fig-0026" title="">Analysis 3.3</a>); change in bone alkaline phosphonate (IU/L) at four months, MD 5.00 (95% CI ‐22.36 to 32.36) and 12 months, MD ‐12.00 (95% CI ‐39.78 to 15.78) (<a href="./references#CD005088-fig-0027" title="">Analysis 3.4</a>); and change in NTX/Cr (nMBCE/mM) at four months, MD ‐108.00 (95% CI ‐300.32 to 84.32) and 12 months, MD ‐111.00 (95% CI ‐269.38 to 47.38) (<a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>) (<a href="./references#CD005088-fig-0028" title="">Analysis 3.5</a>). </p> </section> <section id="CD005088-sec-0095"> <h6 class="title">2. Growth</h6> <p>DiMeglio found no statistically significant difference in height compared to baseline in the oral or IV groups (within‐group data) (<a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>). </p> </section> <section id="CD005088-sec-0096"> <h6 class="title">3. Bone pain</h6> <p>DiMeglio did not investigate bone pain (<a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>). </p> </section> <section id="CD005088-sec-0097"> <h6 class="title">4. Quality of life</h6> <p>DiMeglio did not address quality of life indicators (<a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>). </p> </section> <section id="CD005088-sec-0098"> <h6 class="title">5. Lung function</h6> <p>DiMeglio did not investigate lung function (<a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>). </p> </section> </section> </section> <section id="CD005088-sec-0099"> <h4 class="title">Different doses of oral or IV bisphosphonates</h4> <p>Two trials were included in this comparison (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>). Bishop considered different doses of oral bisphosphonates and Senthilnathan considered different doses of IV bisphosphonates and were therefore not pooled in the analysis (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>). </p> <section id="CD005088-sec-0100"> <h5 class="title">Primary outcomes</h5> <section id="CD005088-sec-0101"> <h6 class="title">1. Fracture incidence</h6> <p>Senthilnathan found no difference in the 6 mg/kg and 12 mg/kg dose in the number of crush‐fractured vertebrae with rate ratio 1.28 (95% CI 0.67 to 2.45) (<a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>) (<a href="./references#CD005088-fig-0029" title="">Analysis 4.1</a>). </p> <p>Bishop found no difference in fracture reduction when comparing each of the three dose groups (0.2, 1, 2 mg/kg/week), RR 0.87 (95% CI 0.48 to 1.57), RR 0.78 (95% CI 0.44 to 1.37), RR 0.89 (95% CI 0.51 to 1.54), respectively (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>) (<a href="./references#CD005088-fig-0030" title="">Analysis 4.2</a>). </p> </section> <section id="CD005088-sec-0102"> <h6 class="title">2. Change in BMD as assessed by DEXA</h6> <p>Senthilnathan found no difference in lumbar spine BMD at 12 months between the different doses, MD 45.00 (95% CI ‐30.15 to 120.15) (<a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>) (<a href="./references#CD005088-fig-0031" title="">Analysis 4.3</a>). </p> <p>Bishop found a statistically significant difference in lumbar spine z score BMD adjusting for the baseline value of each outcome and age when comparing 0.2 mg/kg versus 2 mg/kg, MD ‐1.18 (95% CI ‐1.97 to ‐0.39) (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>) (<a href="./references#CD005088-fig-0032" title="">Analysis 4.4</a>). No difference was found at remaining two dose groups: 0.2 mg/kg/week versus 1 mg/kg/week, MD ‐0.50 (95% CI ‐1.29 to 0.29); 1 mg/kg/week versus 2 mg/kg/week, MD ‐0.68 (95% CI ‐1.46 to 0.10) (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>) (<a href="./references#CD005088-fig-0032" title="">Analysis 4.4</a>). </p> </section> </section> <section id="CD005088-sec-0103"> <h5 class="title">Secondary Outcomes</h5> <section id="CD005088-sec-0104"> <h6 class="title">1. Change in biochemical markers of bone and mineral metabolism and bone histology</h6> <p>In the Senthilnatahn trial, the mean (SD) serum bone specific ALP declined from 235 (49) IU/l at baseline to 170 (46) IU/l at 12 months, remaining well above the upper limit of the adult normal range (48 IU/l). NTx fell from 2089 (1612) to 551 (120) nmol BCE/mmol creatinine over the same period. In percentage terms, ALP fell by 28% (17%) and NTx by 74% (27%) (<a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>). </p> <p>In the Bishop trial, bone specific alkaline phosphatase activity declined by 1% from 81 ± 28 to 80 ± 39 IU/l (maximum decline for any child was 63%) and NTx by 21% from 2575 ± 1618 to 2044 ± 1031 nmol/mmol BCE (maximum decline for any child 70%) over the two‐year period of the trial (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>). </p> </section> <section id="CD005088-sec-0105"> <h6 class="title">2. Growth</h6> <p>Senthilnathan reported no difference in final length z score between the two dose groups, MD 2.10 (95% CI ‐0.50 to 4.70) (one trial) (<a href="./references#CD005088-fig-0033" title="">Analysis 4.5</a>) (<a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>). Bishop also found no difference in height z score for the three dose groups (0.2, 1, 2 mg/kg/week) at two years, (MD ‐0.56 (95% CI ‐2.46 to 1.34) (one trial), MD ‐1.15 (95% CI ‐2.87 to 0.57) (one trial), MD ‐0.59 (95% CI ‐2.34 to 1.16,) (one trial), respectively (<a href="./references#CD005088-fig-0034" title="">Analysis 4.6</a>) (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>). </p> </section> <section id="CD005088-sec-0106"> <h6 class="title">3. Bone pain</h6> <p>Bishop found no difference between the groups in pain scores but no data was presented (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>). Senthilnathan did not measure bone pain (<a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>). </p> </section> <section id="CD005088-sec-0107"> <h6 class="title">4. Quality of life</h6> <p>Bishop reported that there were no statistically significant differences in PEDI and Gross Motor Function Measure scores between the groups. Mean (SD) grip strength in the right and left hands respectively was 33.6 (23.9) lb and 31.8 (21.6) lb at trial initiation and 38.4 (20.9) lb and 39.3 (21.8) lb at trial end. Neither difference was statistically significant and data are not presented separately for each treatment group (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>). </p> <p>Senthilnathan did not measure quality of life outcomes (<a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>). </p> </section> <section id="CD005088-sec-0108"> <h6 class="title">5. Lung function</h6> <p>Neither of the included trials reported on this outcome (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>). </p> </section> </section> </section> <section id="CD005088-sec-0109"> <h4 class="title">IV versus IV bisphosphonates</h4> <p>Two trials were included in this comparison which compared zoledronic acid to pamidronate efficacy in OI (<a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>; <a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). </p> <section id="CD005088-sec-0110"> <h5 class="title">Primary outcomes</h5> <section id="CD005088-sec-0111"> <h6 class="title">1. Fracture incidence</h6> <p>The zoledronic acid trial reported that there was no difference in the number of participants with fractures (32 (43%) versus 31 (41%)) (<a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). The trial investigators also reported no difference in the change in number of fractures per participant from baseline, MD ‐0.41 (95% CI ‐1.45 to 0.63) (<a href="./references#CD005088-fig-0035" title="">Analysis 5.1</a>). </p> <p>The Barros trial reported that at the end of the follow‐up period, both groups showed a decrease in the fracture rate (P = 0.025 and P = 0.048, respectively). No further data were reported (<a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>). </p> </section> <section id="CD005088-sec-0112"> <h6 class="title">2. Change in BMD as assessed by DEXA</h6> <p>The zoledronic trial reported a statistically significant change in lumbar spine BMD, MD 8.06 (95% CI 0.48 to 15.64) favouring zoledronic acid (<a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>) (<a href="./references#CD005088-fig-0036" title="">Analysis 5.2</a>). </p> <p>The Barros trial appears to favour pamidronate in the analysis, MD ‐1.50 (95% CI ‐2.86 to ‐0.14) (<a href="./references#CD005088-fig-0036" title="">Analysis 5.2</a>), however, the trial report indicates that compared with the pamidronate group, the zoledronic acid group had a significant increase in lumbar spine z score at one year (P = 0.053) (<a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>). </p> </section> </section> <section id="CD005088-sec-0113"> <h5 class="title">Secondary Outcomes</h5> <section id="CD005088-sec-0114"> <h6 class="title">1. Change in biochemical markers of bone and mineral metabolism and bone histology</h6> <p>The zoledronic trial reported there was a statistically significant reduction in CTx , P1NP and BSALP in the zoledronic group compared to the pamidronate group at both six and 12 months (<a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). </p> <p>There was no significant difference in osteocalcin (OC) or serum CTx between the groups. Data on other markers are reported in 'Table 2' of the trial report (<a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>). </p> </section> <section id="CD005088-sec-0115"> <h6 class="title">2. Growth</h6> <p>The increases in both supine length and vertebral spine length were numerically greater in the pamidronate group compared to the zoledronic acid group, but the results were not statistically significant: MD ‐0.50 (95% CI ‐2.62 to 1.62) (<a href="./references#CD005088-fig-0037" title="">Analysis 5.3</a>); MD ‐0.80 (95% CI ‐2.39 to 0.79), respectively (<a href="./references#CD005088-fig-0038" title="">Analysis 5.4</a>). Height was not adjusted for age so it was not possible to tell from the data if there was an improvement in growth (z score) in those on bisphosphonates (<a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). </p> <p>In the Barros trial, there was no significant change in height in both groups throughout the treatment (pamidronate 111.7 (30.3) versus zoledronic acid 97.0 (16)). It is not clear what the number of participants were in each group so this data could not be included in the forest plot (<a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>). </p> </section> <section id="CD005088-sec-0116"> <h6 class="title">3. Bone pain</h6> <p>In one trial, bone pain was assessed using the Wong‐Baker FACES at baseline, 6 and 12 months and did not identify a clear increase in bone pain compared to baseline nor did it identify a clear difference between treatment groups (<a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). Most participants had no pain or minimal pain at baseline and at the end of the trial. Data are fully reported but were not summarised. Pain was also reported as an adverse event that occurred in at least 10% of participants in either treatment group (safety population, zoledronic acid 17.6% versus pamidronate 5.1%). </p> <p>The Barros trial did not report on this outcome (<a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>). </p> </section> <section id="CD005088-sec-0117"> <h6 class="title">4. Quality of life</h6> <p>Neither of the included trials reported on this outcome (<a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>; <a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). </p> </section> <section id="CD005088-sec-0118"> <h6 class="title">5. Lung function</h6> <p>Neither of the included trials reported on this outcome (<a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>; <a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005088-sec-0119" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005088-sec-0119"></div> <section id="CD005088-sec-0120"> <h3 class="title" id="CD005088-sec-0120">Summary of main results</h3> <p>Fourteen trials were included in this review; 12 of these enrolled children (<a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>; <a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>; <a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>; <a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>; <a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>) and two enrolled adults (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>). To varying degrees, these studies investigated changes in BMD, fracture rate, markers of bone turnover, growth, pain and quality of life with bisphosphonate therapy. For a summary of outcomes reported, see 'Additional tables' (<a href="#CD005088-tbl-0005">Table 5</a>). </p> </section> <section id="CD005088-sec-0121"> <h3 class="title" id="CD005088-sec-0121">Overall completeness and applicability of evidence</h3> <p>All trials assessing BMD independently reported statistically significant increases after treatment with either oral or IV bisphosphonate and sometimes at separate sites (spine, hip, femur). However, it is difficult to compare these trials directly as different populations were included (adults versus children; for accurate comparisons children cannot be compared to adults due to high bone turnover during childhood and adolescence and open epiphyses). Additionally, different reporting indices were used (z score versus t score versus total BMD). As previously mentioned, the expected growth and BMD increases in children and adolescents with OI, coupled with their tendency for decreased fractures, make data comparison challenging. Statistically significant gains in spine and hip BMD were not seen with IV bisphosphonate administration at six and 12 months with combined summary statistics, indicating the need for continued rigorous study (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>). Interestingly, multiple trials reported the largest gains in BMD in the first year of therapy (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>; <a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>) and gains in BMD were independent of administration of therapy in a placebo‐controlled cross‐over trial (<a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>). Two trials showed greater increases with higher dosing (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>); one of which showed a statistically significant increase in BMD only at the higher dosing schedule (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>). These data possibly argue for the study and consideration of short‐course bisphosphonate therapy. When oral and IV bisphosphonates were directly compared, both statistically significantly increased spine BMD z scores at 12 and 24 months, but there were no differences in BMD between groups when route of administration was considered (<a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>) (<a href="./references#CD005088-fig-0025" title="">Analysis 3.2</a>). </p> <p>The combined data analyses supporting a change in fracture incidence after bisphosphonate therapy are less straightforward. Adami reported a 14% reduction of fractures after adults were treated with IV neridronate (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>). Sakkers found a 31% reduction in the relative risk of fracture of long bones after treatment with oral olpadronate in children affected with OI (<a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>). Relative risk of fracture was also reduced by 0.36% in another trial (<a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>). Seikaly noted a non‐significant trend toward decreased fractures (<a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>). DiMeglio found no differences in fracture incidence with oral versus IV bisphosphonate administration and noted a decreased fracture incidence with time, but only when oral and IV groups were combined (<a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>). Letocha found decreased upper extremity but not lower extremity fracture rates in the first year of therapy but no further increases were noted when therapy was extended (<a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>). Bishop reported an overall tendency to reduced fracture incidence when compared to the fracture incidence over the prior two years. They noted no statistically significant difference between the dose of oral bisphosphonates (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>). A larger trial by Bishop reported statistically significant difference in fracture incidence between children treated with risedronate and the placebo control group; 31% versus 49% respectively. However, during the following two years of open‐label study, the same groups reported fracture incidence of 53% and 65% respectively (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>). Chevrel found no difference in vertebral or peripheral fracture rates but was not adequately powered to detect a difference (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>). A further three trials did not identify a statistically significant difference in fracture incidence, although the Senthilnathan trial did make note of an improvement in infant spinal crush fracture (<a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>). It should be noted that none of the 14 included trials reported increased fractures with bisphosphonate treatment. When we further analysed the number of participants with at least one fracture, we found no difference in fractures in those treated with IV neridronate compared to the control population (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>) (<a href="./references#CD005088-fig-0014" title="">Analysis 2.1</a>). These trials employed retrospective fracture recall as a method for comparison, leading to potential recall bias. The number of participants randomised versus those lost to follow up was also unclear in one trial (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>). Consideration of reported heterogeneous results, in addition to the aforementioned natural tendency toward reduction in fractures with age highlight the importance of continued prospective, placebo‐controlled evaluation of bisphosphonates and fracture incidence in children. This is possible given widespread bisphosphonate use. </p> <p>All 14 trials measured serum and urine markers (or both) of either bone formation or resorption (or both). The trials did not focus on the same biochemical markers, but each applied best practice with respect to sample collection and remained consistent to the marker chosen to represent bone turnover. Twelve trials reported decreases in serum (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>; <a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>; <a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>; <a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>; <a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>) or urine type I collagen by products (<a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a>; <a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>) whereas two trials reported no statistical difference in biochemical markers of bone turnover between treatment and control groups or from baseline (<a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>). The clinical significance and utilization of these biochemical markers of bone turnover are not universally utilized, however, the assumption is they act as a proxy for efficacy of therapy. These markers are not specific to process but indicate a change in bone homeostasis and are not reliable indicators of acute change. The varied markers chosen for study in the trials we reviewed prohibited direct comparison, but more systematic study of these markers could assist investigators in assessing response to individual bisphosphonates and their dosing, as well as participant compliance or concordance, or both, with therapy. </p> <p>Bisphosphonate therapy was not conclusively shown to impact vertical growth. Ten trials included in this review commented on growth. Seikaly reported increased height z scores with oral bisphosphonates (<a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>). Growth as assessed by height and length combined z scores compared to normal children was increased in another trial when children receiving oral and IV therapies were combined (<a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>). Letocha found growth rates were unchanged by bisphosphonate therapy (<a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>). Seated height and vertebral height were also not different in the treatment versus placebo group of another trial (<a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>). Two trials compared different bisphosphonates to one another and did not show a significant difference in vertical growth rates between the therapies under investigation, they however did not compare data to normalized standards and thus no commentary can be made on their impact on vertical growth (<a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>; <a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). No difference in z scores were noted in the remaining five trials (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>). It is not within the scope of this review to distinguish between bisphosphonate responsiveness in different OI types, however it is interesting to note that milder forms of OI showed more improvements in growth and BMD in at least one trial (<a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>). </p> <p>It is important to determine whether bisphosphonate administration translates into functional changes. Bone pain and quality of life were addressed in several trials. Decreased pain scores and decreased analgesic use were reported in one trial (<a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>). The remaining trials which included pain and other quality of life measures found no difference in self‐reported pain scores (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>; <a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>; <a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). The exception within these data was of increased pain with bisphosphonates at 36 months only (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>). When the authors re‐evaluated this difference, they found it statistically significant in the intention‐to‐treat analysis, but not in the per protocol analysis. Seikaly found improved well‐being scores and increases in self‐care abilities but no change in mobility (<a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>). However, Sakkers found no changes in self‐care abilities, nor did the authors find changes in strength or mobility when compared to placebo controls (<a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>). Additionally, no differences in gross motor abilities or other quality of life measures were found in several trials (<a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a>; <a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a> ; <a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>). Chevrel was the only trial to assess hearing and found no change in Rinne testing with bisphosphonate therapy (<a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a>). Taken together, the data presented here do not support consistent improvements in these quality of life indicators with bisphosphonate administration. Nevertheless, clinicians caring for people affected by OI have the strong anecdotal impression bisphosphonate treatment results in reduction in pain and subsequent increased mobility and functionality. These secondary outcomes were assessed by a few trials in this review, but represent an important need in future research. One may argue fracture rates may not be the only appropriate primary outcome of interest if a population with fragile bones were to have increased mobility as a result of treatment. It is difficult to quantify general well‐being, perhaps a more granular analysis needs to be developed looking at participation in daily events with less emphasis on pain. </p> <p>Trials including IV and oral bisphosphonate use were included in this review. Mean bisphosphonate oral bioavailability (alendronate) in children is comparable to that found in adult trials, with approximately 50% localizing to bone (<a href="./references#CD005088-bbs2-0022" title="WardLM , DenkerAE , PorrasA , ShugartsS , KlineW , TraversR , et al. Single‐dose pharmacokinetics and tolerability of alendronate 35‐ and 70‐milligram tablets in children and adolescents with osteogenesis imperfecta type I. Journal of Clinical Endocrinology and Metabolism2005;90(7):4051‐6. ">Ward 2005</a>). However, individual oral bioavailability of alendronate varies as much as ten‐fold and could contribute to variable responsiveness (<a href="./references#CD005088-bbs2-0022" title="WardLM , DenkerAE , PorrasA , ShugartsS , KlineW , TraversR , et al. Single‐dose pharmacokinetics and tolerability of alendronate 35‐ and 70‐milligram tablets in children and adolescents with osteogenesis imperfecta type I. Journal of Clinical Endocrinology and Metabolism2005;90(7):4051‐6. ">Ward 2005</a>). It was noted that there was a large individual variance in bioavaliability of zolendronate in children, but there was no apparent effect of gender, body weight or creatinine clearance in participants with normal renal function (<a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). We did not separately assess different bisphosphonate preparations although we have distinguished between oral and IV therapy. Different preparations and pharmacogenetic variability potentially underlie heterogeneous responses in individual participants. Additionally, although we made no attempt to distinguish between OI type and response to bisphosphonate therapy, it is entirely plausible different OI types will respond to therapy differently as one trial suggests (<a href="./references#CD005088-bbs2-0018" title="DiMeglioLA , FordL , McClintockC , PeacockM . Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone2004;35(5):1038‐45. ">DiMeglio 2004</a>). </p> <p>Although specific data were not extracted, bisphosphonate therapy administered for one to three years appears to be safe and well‐tolerated in the adults and children treated here. Adverse effects of bisphosphonates are few and minor in this population (gastrointestinal complaints ‐ often comparable to placebo in the trials we reviewed, fever, headache, small decreases in lymphocyte counts) and the drugs are generally well‐tolerated (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>; <a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>; <a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a>; <a href="./references#CD005088-bbs2-0022" title="WardLM , DenkerAE , PorrasA , ShugartsS , KlineW , TraversR , et al. Single‐dose pharmacokinetics and tolerability of alendronate 35‐ and 70‐milligram tablets in children and adolescents with osteogenesis imperfecta type I. Journal of Clinical Endocrinology and Metabolism2005;90(7):4051‐6. ">Ward 2005</a>; <a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a>; <a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a>; <a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). Flu‐like symptoms described as "acute phase reactions" were common with IV administration of bisphosphonates, particularly with the first infusion (<a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a>; <a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a>; <a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>) but rarely contributed to trial withdrawal. Intravenous access was difficult in one trial not included in this review where four of nine children less than three years required central line placement for IV bisphosphonate administration (<a href="./references#CD005088-bbs2-0018" title="DiMeglioLA , FordL , McClintockC , PeacockM . Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone2004;35(5):1038‐45. ">DiMeglio 2004</a>). Intravenous access was otherwise not reported to be problematic in children or adults. Clinical and laboratory evidence of hypocalcemia was reported in the zoledronic acid clinical trial which identified 22% of the participants treated with zolderonic acid and 9% of participants treated with pamidronate to have hypocalcemia (<a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a>). However, clinical or laboratory evidence of hypocalcemia was not found (<a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>; <a href="./references#CD005088-bbs2-0022" title="WardLM , DenkerAE , PorrasA , ShugartsS , KlineW , TraversR , et al. Single‐dose pharmacokinetics and tolerability of alendronate 35‐ and 70‐milligram tablets in children and adolescents with osteogenesis imperfecta type I. Journal of Clinical Endocrinology and Metabolism2005;90(7):4051‐6. ">Ward 2005</a>) nor was evidence of hepatic or renal dysfunction or changes in nephrocalcinosis as measured by ultrasound in those treated with bisphosphonates (<a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a>; <a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a>; <a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a>). Emerging data from clinical trials and observational studies do, however, support a concern for bisphosphonate use and atypical subtrochanteric femur fractures (<a href="./references#CD005088-bbs2-0039" title="ErvitiJ , AlonsoA , OlivaB , GorrichoJ , LópezA , TimonerJ , et al. Oral bisphosphonates are associated with increased risk of subtrochanteric and diaphyseal fractures in elderly women: a nested case–control study. http://bmjopen.bmj.com/content/3/1/e002091 (accessed 06 February 2013). ">Erviti 2013</a>). The optimal method, dose, initiation and duration of therapy remain unclear. However, IV neridronate has been administered to infants with OI as young as neonates with reported improved growth and lowered fracture incidence (<a href="./references#CD005088-bbs2-0016" title="AntoniazziF , ZamboniG , LauriolaS , DonadiL , AdamiS , TatoL . Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. Journal of Pediatrics2006;149(2):174‐9. ">Antoniazzi 2006</a>). A more extensive safety review of bisphosphonate use in children with low BMD and fragility fractures in juvenile idiopathic arthritis has been recently published (<a href="./references#CD005088-bbs2-0061" title="ThorntonJ , AshcroftDM , MughalMZ , ElliottRA , O'NeillTW , SymmonsD . Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis. Archives of Disease in Childhood2006;91(9):753‐61. ">Thornton 2006</a>). A rare, but serious side effect of bisphonates is osteonecrosis of the jaw. This presumably occurs from over‐suppression of bone turnover and occurs more commonly in elderly people with cancer taking primarily IV bisphosphonates (<a href="./references#CD005088-bbs2-0064" title="WooSB , HellsteinJW , KalmarJR . Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Annals of Internal Medicine2006;144(10):753‐61. ">Woo 2006</a>). To our knowledge, osteonecrosis of the jaw has not been reported in children or adults with OI. </p> <p>We identified a recent abstract outlining an RCT evaluating subcutaneous teriparatide in adults (<a href="http://www.ashg.org/2013meeting/abstracts/fulltext/f130121209.htm" target="_blank">www.ashg.org/2013meeting/abstracts/fulltext/f130121209.htm</a>). These data show statistically significant changes in BMD as well as significant changes in markers of bone metabolism. No comment was made of fracture incidence but as this data has not yet been published in a peer‐review journal, further analysis and discussion of this data was not undertaken. The use of parathyroid analogues is further supported by another recent publication where individuals who continued to fracture after bisphosphonate therapy were treated with teriparatide and showed a positive response in biomarkers (<a href="./references#CD005088-bbs2-0042" title="GattiD , RossiniM , ViapianaO , PovinoMR , LiuzzaS , FracassiE , et al. Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcified Tissue International2013;93(5):448‐52. ">Gatti 2013</a>). To date, the focus of pharmacological treatment for OI has been on bisphosphonates. Byers reviewed pharmacological agents used prior to 1991 (<a href="./references#CD005088-bbs2-0028" title="ByersPH , SteinerRD . Osteogenesis imperfecta. Annual Review of Medicine1992;43:269‐82. ">Byers 1992</a>). </p> </section> <section id="CD005088-sec-0122"> <h3 class="title" id="CD005088-sec-0122">Quality of the evidence</h3> <p>Nineteen studies were identified and reviewed, 14 of which were randomised control trials and met the inclusion criteria. These 14 trials represent a total of 819 participants. The majority of trials analysed were small and not powered to show a statistically significant difference in many outcome measures. The primary and secondary outcome measures were reasonably evenly represented within these trials, methodologies varied and direct comparison of data was at times not possible. Meta‐analysis of the available data was limited due to the different agents used (oral versus IV bisphosphonates), different outcome measures, different populations (adults versus children), different reporting indices (z score versus t score versus total BMD), and variable inclusion of a placebo or control group. Sufficient commonality existed amongst the stated primary and secondary outcomes to enable reliable data comparison to internal validation of conclusions drawn. </p> </section> <section id="CD005088-sec-0123"> <h3 class="title" id="CD005088-sec-0123">Potential biases in the review process</h3> <p>This version of the review has used the Cochrane risk of bias assessment as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions 5.1</i> (<a href="./references#CD005088-bbs2-0047" title="HigginsJPT , Altman DG(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). </p> <p>As stated above, the meta‐analysis was limited due to the variability across the studies and potential biases were acknowledged during this analysis and subsequent data extrapolation. </p> </section> <section id="CD005088-sec-0124"> <h3 class="title" id="CD005088-sec-0124">Agreements and disagreements with other studies or reviews</h3> <p>One other relevant review has been published (<a href="./references#CD005088-bbs2-0033" title="CastilloH ,  Samson‐FangL ,  American Academy for Cerebral Palsy and Developmental Medicine Treatment Outcomes Committee Review Panel. Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Developmental Medicine and Child Neurology2009;51(1):17‐29. ">Castillo 2009</a>). The authors reviewed seven studies and concluded that the studies favoured an overall improvement in BMD but that fracture reduction and growth improvement were not universally supported. They additionally concluded that further studies were required to evaluate the broader impact of therapy, including, but not limited to, deformity, daily function and quality of life. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005088-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral bisphosphonates versus placebo, Outcome 1 Fracture risk reduction." data-id="CD005088-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Oral bisphosphonates versus placebo, Outcome 1 Fracture risk reduction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral bisphosphonates versus placebo, Outcome 2 Rate of fractures." data-id="CD005088-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Oral bisphosphonates versus placebo, Outcome 2 Rate of fractures.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral bisphosphonates versus placebo, Outcome 3 Number of people with at least one fracture." data-id="CD005088-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Oral bisphosphonates versus placebo, Outcome 3 Number of people with at least one fracture. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral bisphosphonates versus placebo, Outcome 4 Mean change (z score) in spine BMD (DEXA)." data-id="CD005088-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Oral bisphosphonates versus placebo, Outcome 4 Mean change (z score) in spine BMD (DEXA). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral bisphosphonates versus placebo, Outcome 5 Mean % change in spine BMD (DEXA)." data-id="CD005088-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Oral bisphosphonates versus placebo, Outcome 5 Mean % change in spine BMD (DEXA). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral bisphosphonates versus placebo, Outcome 6 Mean % change in total femur BMD (DEXA)." data-id="CD005088-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Oral bisphosphonates versus placebo, Outcome 6 Mean % change in total femur BMD (DEXA). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral bisphosphonates versus placebo, Outcome 7 Change in height." data-id="CD005088-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Oral bisphosphonates versus placebo, Outcome 7 Change in height.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral bisphosphonates versus placebo, Outcome 8 Change in bone pain scores." data-id="CD005088-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Oral bisphosphonates versus placebo, Outcome 8 Change in bone pain scores.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral bisphosphonates versus placebo, Outcome 9 Change in analgesic use (days per week)." data-id="CD005088-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Oral bisphosphonates versus placebo, Outcome 9 Change in analgesic use (days per week). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral bisphosphonates versus placebo, Outcome 10 Change in well‐being score." data-id="CD005088-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Oral bisphosphonates versus placebo, Outcome 10 Change in well‐being score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral bisphosphonates versus placebo, Outcome 11 Change in self‐care score (PEDI)." data-id="CD005088-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Oral bisphosphonates versus placebo, Outcome 11 Change in self‐care score (PEDI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral bisphosphonates versus placebo, Outcome 12 Change in total mobility score (WeeFIM)." data-id="CD005088-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Oral bisphosphonates versus placebo, Outcome 12 Change in total mobility score (WeeFIM). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Oral bisphosphonates versus placebo, Outcome 13 Hearing (assessed by % rinnie)." data-id="CD005088-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Oral bisphosphonates versus placebo, Outcome 13 Hearing (assessed by % rinnie). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 1 Number of participants with at least one fracture." data-id="CD005088-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 1 Number of participants with at least one fracture. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 2 Incidence of lower extremity fractures." data-id="CD005088-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 2 Incidence of lower extremity fractures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 3 Incidence of upper extremity fractures." data-id="CD005088-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 3 Incidence of upper extremity fractures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 4 Mean % change (from baseline) in spine BMD (DEXA)." data-id="CD005088-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 4 Mean % change (from baseline) in spine BMD (DEXA). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 5 Mean % change (z score) in spine BMD (DEXA)." data-id="CD005088-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 5 Mean % change (z score) in spine BMD (DEXA). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 6 Mean % change in total hip BMD (DEXA)." data-id="CD005088-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 6 Mean % change in total hip BMD (DEXA). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 7 Change in vertical growth (cm/year)." data-id="CD005088-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 7 Change in vertical growth (cm/year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 8 Bone pain scores." data-id="CD005088-fig-0021" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 8 Bone pain scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 9 Muscle strength." data-id="CD005088-fig-0022" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 9 Muscle strength.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 10 BAMF (10‐point gross motor assessment)." data-id="CD005088-fig-0023" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 IV bisphosphonates versus placebo or no treatment, Outcome 10 BAMF (10‐point gross motor assessment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oral versus IV bisphosphonates, Outcome 1 Annualised fracture rates." data-id="CD005088-fig-0024" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Oral versus IV bisphosphonates, Outcome 1 Annualised fracture rates.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oral versus IV bisphosphonates, Outcome 2 Spine BMD z scores." data-id="CD005088-fig-0025" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Oral versus IV bisphosphonates, Outcome 2 Spine BMD z scores.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oral versus IV bisphosphonates, Outcome 3 Change in alkaline phosphonate (IU/liter)." data-id="CD005088-fig-0026" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Oral versus IV bisphosphonates, Outcome 3 Change in alkaline phosphonate (IU/liter). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oral versus IV bisphosphonates, Outcome 4 Change in bone alkaline phosphatase (IU/liter)." data-id="CD005088-fig-0027" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Oral versus IV bisphosphonates, Outcome 4 Change in bone alkaline phosphatase (IU/liter). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Oral versus IV bisphosphonates, Outcome 5 Change in NTX/Cr (nMBCE/mM)." data-id="CD005088-fig-0028" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Oral versus IV bisphosphonates, Outcome 5 Change in NTX/Cr (nMBCE/mM).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Different doses of oral or IV bisphosphonates, Outcome 1 Number of crush‐fractured vertebrae." data-id="CD005088-fig-0029" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Different doses of oral or IV bisphosphonates, Outcome 1 Number of crush‐fractured vertebrae. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Different doses of oral or IV bisphosphonates, Outcome 2 Number of fractures suffered by participant." data-id="CD005088-fig-0030" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Different doses of oral or IV bisphosphonates, Outcome 2 Number of fractures suffered by participant. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Different doses of oral or IV bisphosphonates, Outcome 3 Lumbar spine bone mineral density." data-id="CD005088-fig-0031" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Different doses of oral or IV bisphosphonates, Outcome 3 Lumbar spine bone mineral density. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Different doses of oral or IV bisphosphonates, Outcome 4 Lumbar spine z score BMD." data-id="CD005088-fig-0032" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Different doses of oral or IV bisphosphonates, Outcome 4 Lumbar spine z score BMD. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Different doses of oral or IV bisphosphonates, Outcome 5 Length z score." data-id="CD005088-fig-0033" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Different doses of oral or IV bisphosphonates, Outcome 5 Length z score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Different doses of oral or IV bisphosphonates, Outcome 6 Height z score at 2 years." data-id="CD005088-fig-0034" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Different doses of oral or IV bisphosphonates, Outcome 6 Height z score at 2 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 IV versus IV, Outcome 1 Change in number of fractures per patient from baseline." data-id="CD005088-fig-0035" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 IV versus IV, Outcome 1 Change in number of fractures per patient from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 IV versus IV, Outcome 2 Lumbar spine BMD at month 12." data-id="CD005088-fig-0036" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 IV versus IV, Outcome 2 Lumbar spine BMD at month 12.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 IV versus IV, Outcome 3 Supine height." data-id="CD005088-fig-0037" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 IV versus IV, Outcome 3 Supine height.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005088-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/urn:x-wiley:14651858:media:CD005088:CD005088-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_t/tCD005088-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 IV versus IV, Outcome 4 Vertebral spine length." data-id="CD005088-fig-0038" src="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 IV versus IV, Outcome 4 Vertebral spine length.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/media/CDSR/CD005088/image_n/nCD005088-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD005088-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Classification of osteogenesis imperfecta</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Syndrome names</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b># of subtypes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Subtypes and genetic basis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Previous type</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Classic Non‐deforming OI with Blue Sclerae</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ia ‐ With normal teeth or Opalescent Dentine caused by COL1A1</p> <p>Ib ‐ caused by COL1A2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>I</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Common variable OI with Normal Sclerae</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IVa ‐ caused by COL1A1</p> <p>IVb ‐ caused by COL1A2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OI with calcification in interosseous membranes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V ‐ caused by 5'UTR mutation in IFITM5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>V</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progressively Deforming OI with normal sclerae </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III ‐gene x</p> <p>III‐COL1A1 or COL1A2 inherited as autosomal dominant</p> <p>III ‐ CRTAP, P3H1/LEPRE1, PPIB, FKBP10, SERPINH1, SP7/OSX, SERPINF1 and BMP 1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>III</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>International Nomenclature Committee for Constitutional Disorders of the Skeleton, Australia. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Classification of osteogenesis imperfecta</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/full#CD005088-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005088-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Current bisphosphonates</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bisphosphonate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mechanism of action</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Route of administration</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alendronate* (Fosamax)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clodronate (Bonefos)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral, IV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Etidronate (Didronel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ibandronate (Boniva)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neridronate*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Olpadronate*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral, IV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pamidronate* (Aredia)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Risendronate (Actonel)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiludronate (Skelid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zolendronate (Zometa, Reclast)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nitrogenous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IV</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Nitrogenous bisphosphonates disrupt osteoclast formation, survival and cytoskeletal dynamics. They contain nitrogen (a colourless tasteless odourless element that as a diatomic gas is relatively inert and constitutes 78% of the atmosphere and that is a constituent of organic compounds found in all living tissues). </p> <p>Non‐nitrogenous bisphosphonates initiate osteoclast apoptosis.</p> <p>IV: intravenous</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Current bisphosphonates</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/full#CD005088-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005088-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Search strategy ‐ PubMed 1996 to June 2016</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MESH terms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. osteogenesis imperfecta (827)<br/> 2. randomised controlled trial or Randomized Controlled Trials (49443)<br/> 3. 1 and 2 (4)<br/> 4. from 4 keep (2) </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Search strategy ‐ PubMed 1996 to June 2016</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/full#CD005088-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005088-tbl-0004"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Search strategy ‐ Ovid MEDLINE 1996 to June 2016</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Search terms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. osteogenesis imperfecta (163)<br/> 2. randomised controlled trial (11846)<br/> 3. Randomized Controlled Trials (11906)<br/> 4. Combine 1, 2, 3 (7)<br/> 5. From 7 keep 2 (2) </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Search strategy ‐ Ovid MEDLINE 1996 to June 2016</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/full#CD005088-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005088-tbl-0005"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Study comparison: outcome data reported by individual studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Biochemical markers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BMD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fracture incidence</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Growth</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bone pain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0001" title="AdamiS , GattiD , ColapietroF , FracassiE , BragaV , RossiniM , et al. Intravenous neridronate in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2003;18(1):126‐30. GattiD , ViapianaO , LippolisI , BragaV , PrizziR , RossiniM , et al. Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta. Journal of Bone and Mineral Research2005;20(8):1323‐6. ">Adami 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease in bone‐specific alkaline phosphatase 20%, decrease 25% in serum sCTx, decrease 20% in urinary free‐deoxypyridinoline in IV Neridronate group vs placebo. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase spine BMD 3.0 +/‐ 4.6%, hip 4.3 +/‐ 3.9% vs no significant change placebo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14% decrease in rate of fracture.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0002" title="BarrosER , SaraivaGL , deOliveiraTP , Lazaretti‐CastroM . Safety and efficacy of a 1‐year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2012;25(5‐6):485‐91. ">Barros 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At the end of the follow‐up period, both groups<br/> showed a decrease in the fracture rate (P = 0.025 and P = 0.048,<br/> respectively) but no information was given comparing the groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There<br/> was no significant change in height in both groups throughout<br/> the treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0003" title="BishopN , HarrisonR , AhmedF , ShawN , EastellR , CampbellM , et al. A randomised controlled dose‐ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research2010;25(1):32‐40. ">Bishop 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease in bone‐specific alkaline phosphatase 1%, decrease 21% serum NTx over 2‐year trial period (grouped data). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lumbar spine BMD increased significantly only in the 2 mg/kg/wk group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall reduction in non‐vertebral fracture incidence in all groups during trial as compared to two years prior. Dose groups did not differ. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups in height z scores.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups in pain scores.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups in grip strength or self reported function.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0004" title="BishopN , AdamiS , AhmedSF , AntónJ , ArundelP , BurrenCP , et al. Risedronate in children with osteogenesis imperfecta:a randomised, double‐blind, placebo‐controlled trial. Lancet2013;382(9902):1424‐32. ">Bishop 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The mean values for serum 25‐hydroxyvitamin D and intact parathyroid hormone were within normal ranges,<br/> and the changes from baseline were small at all time‐points<br/> for both treatment groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lumbar spine BMD increased significantly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>significant decrease in risk of recurrent clinical fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups in height z scores.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no difference in pain scales between the groups and the data was not shown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0005" title="ChevrelG , SchottAM , FontangesE , CharrinJE , Lina‐GranadeG , DuboeufF , et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3‐year randomized placebo‐controlled trial. Journal of Bone and Mineral Research2006;21(2):300‐6. ">Chevrel 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease in bone resorption markers (collagen peptides, osteocalcin) at one year. Alkaline phosphatase unchanged. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase spine BMD. Increase femur BMD. Effects seen primarily in first year of therapy.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in vertebral or peripheral fracture rate. Not adequately powered.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in pain except an increase with alendronate at 36 month time point.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0006" title="DiMeglioLA , PeacockM . Two‐year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. Journal of Bone and Mineral Research2006;21(1):132‐40. DimeglioLA , FordL , McClintockC , PeacockM . A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. Journal of Pediatric Endocrinology and Metabolism2005;18(1):43‐53. ">DiMeglio 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease in alkaline phosphatase and bone alkaline phosphatase; decrease in urine NTX/Cr. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase BMD, BMC and area z scores in both oral and IV therapy.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased fracture incidence with time when both groups are combined.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase height and length combined group z scores compared to normal children.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0007" title="GattiD , AntoniazziF , PrizziR , BragaV , RossiniM , TatoL , et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. Journal of Bone and Mineral Research2005;20(5):758‐63. ">Gatti 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant decrease in alkaline phosphatase from baseline. Groups did not differ.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase spine BMD in first 12 months, then groups were no longer different. BMD continued to be different from baseline. Initial increase (first 12 months) in height/projected lumbar spine area, followed by no change at 12 ‐ 26 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Relative risk reduction 0.36% (CI, 0.15 ‐ 0.87; P &lt; 0.02).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Initial increase (first 12 months) in height/projected lumbar spine area, followed by no change at 12 ‐ 26 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0008" title="LetochaAD , CintasHL , TroendleJF , ReynoldsJC , CannCE , ChernoffEJ , et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short‐term functional improvement. Journal of Bone and Mineral Research2005;20(6):977‐86. ">Letocha 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant change from baseline as measured at each infusion time.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase spine BMD in treatment group as compared to control group. Increases were seen in the first 12 months but no further increases were noted with extended therapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased upper extremity fractures in the first year of treatment with no further decrease in the second year. No change in fracture incidence of lower extremity long bone fracture in the first or second year. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Growth rates were unchanged.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in self‐reported pain scores.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in muscle strength or gross motor abilities.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0014" title="Food , Drug Administration(FDA) . Center for Drug Evaluation and Research. Statistical review and evaluation ‐ clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf (accessed 07 April 2014). NCT00063479 . Bisphosphonate treatment of osteogenesis imperfecta. http://clinicaltrials.gov/show/NCT00063479 (accessed 08 March 2013). ">Zoledronic Acid 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The secondary endpoints of relative change from baseline in biomarkers of bone turnover (serum ƒÀ‐CTx, P1NP and BALP, in participants greater than or equal to 3 years of age) all had statistically significant greater reductions in the zoledronic acid group compared to the pamidronate group at both 6 and 12 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The primary analysis of the percentage change in LS BMD at month 12 relative to baseline in the ITT (LOCF) population demonstrated that zoledronic acid was not only non‐inferior, but superior, to pamidronate with an 8% greater increase in LS BMD and both 95% confidence intervals above zero </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups in fractures.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference between groups in mean supine length, mean vertebral spine length and height. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistically significant differences were identified between treatment groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0009" title="RauchF , MunnsCF , LandC , CheungM , GlorieuxFH . Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Bone and Mineral Research2009;24(7):1282–9. ">Rauch 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease collagen type‐1 N‐telopeptide in treatment group compared to placebo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase spine BMD in treatment group compared to placebo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No detectable difference in new fractures.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in height z scores.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in bone pain.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in grip force.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0010" title="SakkersR , KokD , EngelbertR , vanDongenA , JansenM , PruijsH , et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2‐year randomised placebo‐controlled study. Lancet2004;363(9419):1427‐31. [] ">Sakkers 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant change between groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase spine z score 1.67 SD vs no significant change placebo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31% decrease in rate of fracture.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant change.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No significant difference in mobility / ambulation; muscle strength or self care.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0011" title="SeikalyMG , KopanatiS , SalhabN , WaberP , PattersonD , BrowneR , et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. Journal of Pediatric Orthopaedics2005;25(6):786‐91. ">Seikaly 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease in urinary NTX/Cr. No change in serum markers or other urinary markers of bone turnover. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase in BMD z score 0.89 with alendronate compared to ‐0.12 with placebo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐significant trend toward decreased fractures.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased height z scores (0.41 vs 0.11) when alendronate is compared to placebo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased pain scores and decreased use of analgesia.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improved well being scores. Increase in self care. No change in mobility.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0012" title="SenthilnathanS ,  WalkerE ,  BishopNJ . Two doses of pamidronate in infants with osteogenesis imperfecta. Archives of Disease in Childhood2008;93(5):398‐400. ">Senthilnathan 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease in bone specific alkaline phosphatase and serum NTx in both groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase in LSB mass for both groups. Increased LSBMD in 12/mg/kg/yr group after adjustment.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No differences in crush fractured vertebrae between groups. Improved crush fractures in all but one infant. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in length z scores between groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not addressed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005088-bbs2-0013" title="GlorieuxFH , RauchF , WardLM , SmithP , VerbruggenN , HeydonN , et al. Alendronate in the treatment of pediatric osteogenesis imperfecta [abstract]. Journal of Bone and Mineral Research2004;20 Suppl:S12. [] WardLM , RauchF , WhyteMP , D'AstousJ , GatesPE , GroganD , et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo‐controlled study. Journal of Clinical Endocrinology and Metabolism2011;96(2):355‐64. ">Ward 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease in uNTx (62%) compared to placebo (32%).</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increase in LSBMD compared to placebo.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in fractures.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in height z scores.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in bone pain.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference in mobility.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>IV: intravenous<br/> NTX/Cr: N‐linked telopeptides/creatinine<br/> sCTx: serum cross‐laps<br/> vs: versus </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Study comparison: outcome data reported by individual studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/full#CD005088-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005088-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral bisphosphonates versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Fracture risk reduction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 1 year follow up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 2 year follow up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Rate of fractures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Relative rate (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 2 year follow up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Relative rate (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number of people with at least one fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.82, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.48, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mean change (z score) in spine BMD (DEXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.28, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.35, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.70, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mean % change in spine BMD (DEXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [3.87, 10.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.31 [5.01, 29.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.4 [5.44, 13.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mean % change in total femur BMD (DEXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change in height <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 At 12 month (z score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.04, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 At 24 months (z score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.19, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Change in bone pain scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 At 36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Change in analgesic use (days per week) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Change in well‐being score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Change in self‐care score (PEDI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Change in total mobility score (WeeFIM) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Hearing (assessed by % rinnie) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral bisphosphonates versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005088-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">IV bisphosphonates versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants with at least one fracture <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.30, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of lower extremity fractures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Incidence of upper extremity fractures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mean % change (from baseline) in spine BMD (DEXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.96 [‐2.51, 22.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.68 [‐6.08, 35.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mean % change (z score) in spine BMD (DEXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mean % change in total hip BMD (DEXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 06 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.16 [‐3.57, 15.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.27 [‐3.69, 26.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change in vertical growth (cm/year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Bone pain scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Muscle strength <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 BAMF (10‐point gross motor assessment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">IV bisphosphonates versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005088-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oral versus IV bisphosphonates</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Annualised fracture rates <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Spine BMD z scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change in alkaline phosphonate (IU/liter) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 At 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Change in bone alkaline phosphatase (IU/liter) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 At 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Change in NTX/Cr (nMBCE/mM) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 At 4 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 At 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Oral versus IV bisphosphonates</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005088-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Different doses of oral or IV bisphosphonates</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of crush‐fractured vertebrae <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 IV 6 mg/kg versus 12 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of fractures suffered by participant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Oral 0.2 v 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Oral 0.2 v 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Oral 1 v 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Lumbar spine bone mineral density <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 IV 12 mg/kg versus 6 mg/kg at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Lumbar spine z score BMD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Oral 0.2 v 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Oral 0.2 v 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Oral1 v 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Length z score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 IV 12 mg/kg versus 6 mg/kg at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Height z score at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Oral 0.2 v 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Oral 0.2 v 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Oral 1 v 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Different doses of oral or IV bisphosphonates</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005088-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">IV versus IV</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in number of fractures per patient from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Lumbar spine BMD at month 12 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Percentage change from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Areal BMD z score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Supine height <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Vertebral spine length <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">IV versus IV</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005088.pub4/references#CD005088-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005088.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005088-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005088-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005088-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD005088-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD005088-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005088\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005088\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005088\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005088\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005088\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005088\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005088\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005088\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005088\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005088\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005088\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005088\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005088\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005088\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005088\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005088\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005088\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005088\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005088.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005088.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005088.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005088.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005088.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724612352"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005088.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724612356"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005088.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e67113e7ff44a',t:'MTc0MDcyNDYxMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 